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ABSTRACT 
 
Recent studies indicated that regulatory T cells (Tregs) are implicated in 
the suppression of the immune response against tumors. Accumulation of 
Tregs in peripheral blood and in tumor microenvironment has been 
described for patients with various types of cancer. The balance between 
T effector cells and Tregs, both at tumor site or at local draining lymph 
nodes is subverted thus limiting the immune response against cancer and 
restraining the effect of immunotherapy. As concern melanoma, data till 
now available confirm the presence of Tregs at tumor site, however no in 
deep analysis on phenotypic or functional characterization of these cells 
have been provided.  
This thesis is aimed at evaluating the role of CD4+ Tregs in the immune 
response against melanoma either by in vivo or in vitro approaches.  
Among molecules found in mice as expressed by Tregs, lymphocytes 
activation gene-3 (LAG-3) has been described to be expressed by 
activated Tregs and more in general as a molecule involved in the control 
of T cell expansion and homeostasis. In this thesis I explored the 
expression of LAG-3 in human CD4+ T cells and found that LAG-3 
identifies a discrete subset of CD4+CD25highFoxp3+ T cells. This 
CD4+CD25highFoxp3+LAG-3+ population is preferentially expanded in 
lymphocytes of tumor-invaded lymph nodes and in lymphocytes 
infiltrating visceral and sub cute metastasis of melanoma patients. Ex-
vivo analysis showed that CD4+CD25highFoxp3+LAG-3+ T cells are 
functionally active cells that release the immunosuppressive cytokines 
interleukin-10 (IL-10) and transforming growth factor beta (TGF-β1). An 
in vitro suppression assay using CD4+CD25highLAG-3+ T cells sorted 
from in vitro expanded CD4+CD25high Tregs showed that this subset of 
cells is endowed with potent suppressor activity that requires cell-to-cell 
contact. All together, our data show that LAG-3 defines an active 
CD4+CD25high Tregs subset in melanoma patients whose frequency is 
expanded at tumor sites. 
My data showed that Tregs are accumulated in different immunological 
districts of patients with melanoma and they also stress the notion that in 
melanoma patients these Tregs are preferentially in an activation status. 
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However, the real impact of these cells on tumor progression has not 
been totally clarified. 
To get insights on the relevance of  Tregs in the immunological response 
to tumor, a phase II randomized trial of multipeptide vaccination in stage 
IIB-C/III melanoma patients has been designed to include the 
administration of  low dose cyclophosphamide (CTX; 300mg/m2) and 
low dose interleukin-2 (IL-2; 3x106). CTX has been described as limiting 
the expansion of Tregs, while IL-2 was given with the aim of expanding 
tumor-specific responses.  The modulation that these drugs exert on 
different T cell compartment, namely Tregs and conventional T cells was 
evaluated for its impact on patients’ immunological response.  
Careful ex-vivo immunological monitoring has been performed aimed at 
assessing the status of vaccine-induced immune response and the levels 
of Tregs. Importantly, Treg frequency was defined combining physical 
and functional markers trying to take into account the plasticity of this 
population. We observed that CTX has a limited efficacy and a transient 
effect on Tregs modulation; frequency of Tregs identified by 
multiparametric fluorescence-activated cell sorting (FACS) analysis as 
CD4+CD25highFoxp3+ dropped in peripheral blood mononuclear cells 
(PBMCs) collected 4-7 days after CTX administration, with 6 out of 13 
patients displaying a reduction ranging from 20 to 65 %. IL-2 showed 
higher immunomodulatory effects, expanding both circulating 
conventional activated CD4+ T cells and Tregs; interestingly, a fraction 
of these Tregs displayed a Th-1 like phenotype, expressing ex-vivo T-bet 
(Th1 specific T-box transcription factor) and interferon-γ (INF-γ).  
Importantly, this enhanced frequency of Tregs does not significantly 
affect patients’ immunization assessed ex-vivo by human leukocyte 
antigen (HLA)-A*0201/peptide multimer staining and IFN-γ ELISpot 
assays.  
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AIMS OF THE PROJECT 
 
Aim of this thesis is to gain insights into the functional features of Tregs 
present at tumor sites, in tumor draining lymph nodes and in peripheral 
blood of melanoma patients. This study is mainly committed to evaluate 
two hypotheses:  
 
- that LAG-3 molecule could be a marker for a subset of human 
Tregs. If so, to verify the hypothesis that LAG-3+ Tregs may 
represent a tumor-associated Treg population;   
 
- that Tregs would exert an actual role on melanoma immunity, 
with the final goal of understanding whether their elimination or 
down-modulation by pharmacological treatments can be of any 
benefit to immunological therapies.  
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STATE OF THE ART 
 
1. MELANOMA 
 
1.1 Epidemiology  
Cutaneous melanoma, also referred to as “malignant melanoma”, 
represents 3-7% of all skin malignancies and is the most serious form of 
skin cancer because of its propensity for early invasion and widespread 
metastasis. With early detection and treatment, the cure rate of melanoma 
is about 95%, but advanced melanoma appears to be resistant to 
conventional therapies and, despite the overall advances in the fields of 
tumor biology and oncology therapies, prognosis for patients with widely 
metastatic disease remains poor, with a median survival rate of 6 months 
and 5-year survival rate of less than 5% (Cummins et al, 2006). 
 
1.2 Pathological staging of melanoma  
In 2001 the American Joint Committee on Cancer (AJCC) Tumor-Nodes-
Metastasis (TNM) staging classification incorporated Breslow depth, 
Clark’s level, ulceration and pathological micro-staging attributes. The 
TNM classification is widely used to describe many human cancers. In 
general T refers to the primary tumor size, N describes the involvement 
of regional lymph nodes, and M indicates the presence or absence of 
distant metastases. Paralleling the staging system for other cancers, 
melanoma patients with localized disease are characterized as stage I or 
II, those with regional metastases are considered stage III, and those with 
distant metastases are considered IV. To characterize the primary tumor, 
T in melanoma uses Breslow Depth (Breslow, 1970), Clark’s level (Clark 
et al, 1969) and the presence or absence of ulceration.  
Breslow depth is measured in millimeters and can be divided in T1 
(<1.0mm), T2 (1.01 to 2.0mm), T3 (2.01 to 4.0mm), T4 (>4.0mm). 
Clark’s level describes the depth of invasion and is useful for prognostic 
differentiation of T1 lesions. Level I is limited to the epidermis (in situ 
melanoma); Level II reaches the papillary dermis; Level III fills the 
papillary dermis; Level IV involves the reticular dermis; Level V 
penetrates within the subcutaneous fat. Tumors that have a Breslow depth 
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of less than 1mm and have a Clark’s level of II or III without ulceration 
remain T1a melanomas; T1b melanomas are ulcerated or have a Clark’s 
level IV or V. A final version of the 2009 AJCC staging and 
classification of melanoma included the mitotic index as a prognostic 
factor in stratifying T1 melanoma. Primary tumor mitotic rate was 
introduced as a major criterion for melanoma staging and prognosis that 
replaces the Clark’s level invasion, and is now proven to be an important 
independent adverse predictor of survival (Balch et al., 2009).   
The N category considers the status of regional lymph nodes. Stages I or 
II do not include any nodal or metastatic involvement. For Stage III 
melanoma, the number and dimension (micrometastasis versus 
macrometastasis) of nodal metastases or the presence of in-transit 
metastases (lesions that reside more than 5 cm from the primary tumor) 
or satellite lesions (lesions that reside within 5 cm from the primary 
tumor) are the most significant predictors of outcomes.  
Distant metastases characterize Stage IV melanomas and can occur in 
skin and subcutaneous tissues, distant lymph nodes (M1a), lung (M1b), 
and other visceral organs (M1c) (Table 1).  
In the absence of nodal or distant metastases, tumor thickness, mitotic 
rate and presence or absence of ulceration remain the best predictors of 
survival outcome (Balch et al, 2011). 
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Table 1. Pathological Staging of Melanoma (Adapted from Balch et al. 2011) 
Pathologic 
Stage 
TNM 
Thickness 
(mm) 
Ulceration 
No 
Positive 
Nodes 
Nodal 
Type 
Distant 
Metastasis 
Surv % 
5Years 
Surv % 
10Years 
IA T1a ≤1 No 0 - - 95.3 87.9 
IB 
T1b ≤1 
Yes or 
Level IV,V 
0 - - 90.9 83.1 
 T2a 1.01-2.0 No 0 - - 89.0 79.2 
IIA T2b 1.01-2.0 Yes 0 - - 77.4 64.4 
 T3a 2.01-4.0 No 0 - - 78.7 63.8 
IIB T3b 2.01-4.0 Yes 0 - - 63.0 50.8 
 T4a >4.0 No 0 - - 67.4 53.9 
IIC T4b >4.0 Yes 0 - - 45.1 32.3 
IIIA N1a Any No 1 Micro - 69.5 63.0 
 N2a Any No 2-3 Micro - 63.3 56.9 
IIIB N1a Any Yes 1 Micro - 52.8 37.8 
 N2a Any Yes 2-3 Micro - 49.6 35.9 
 N1b Any No 1 Macro - 59.0 47.7 
 N2b Any No 2-3 Macro - 46.3 39.2 
IIIC N1b Any Yes 1 Macro - 29.0 24.4 
 N2b Any Yes 2-3 Macro - 24.0 15.0 
 N3 Any Any 4 Micro/Macro - 26.7 18.4 
IV M1a Any Any Any Any Skin/SQ 18.8 15.7 
 M1b Any Any Any Any Lung 6.7 2.5 
 
M1c Any any any any 
Other 
visceral 
9.5 6.0 
 
1.3 Systemic therapy for melanoma 
Surgical excision is the treatment of choice for melanoma, especially for 
early stages of disease, and systemic chemotherapy remains the most 
widely used treatment, especially when metastatic sites are not surgically 
accessible, but melanoma are less sensitive to standard treatment than 
other cancers.  
 
1.3.1 Chemotherapy of melanoma 
Traditional systemic chemotherapy has failed to significantly improve the 
survival of patients with non-resectable metastatic melanoma (Bajetta et 
al, 2002). Chemotherapy drugs more commonly used to treat melanoma 
include Dacarbazine (DTIC) and Temozolomide (TMZ). Response rate 
of DTIC as single agent ranges from 15% to 25%, but these responses 
have in general brief duration (3-6 months) and the complete response 
rate is only 5% (Lee et al., 1995). TMZ was shown to have a slightly 
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higher response rate (13.5% vs 12.1%) and median survival (7.7 vs 6.4 
moths) than DITC, neither of which was statistically significant 
(Middleton et al., 2000).  DTIC is also used with other chemotherapy 
drugs such as Carmustine (BCNU) and cisplatin. Cisplatin, vinblastine, 
and DTIC is another chemotherapy combination for treating melanoma. 
These chemotherapy drugs may also be combined with immunotherapy 
drugs, such as interferon alpha (IFN-α) and/or IL-2. 
1.3.2 Cancer immunotherapy 
Melanoma is one of the most immunogenic types of cancer, in fact 
several melanoma-specific antigens have been identified (Table 2) and 
large number of melanoma specific antibodies and functional 
lymphocytes are present in patients with melanoma (Boon et al., 2006); 
moreover, metastatic melanoma patients respond to immune-stimulating 
agents, such as interferons and IL-2 (Garbe et al., 2011) and spontaneous 
regression of melanoma with simultaneous onset of vitiligo has been 
reported (Speeckaert et al., 2011). 
For this reason immunotherapy has been largely used in the last decades 
as experimental therapy to treat melanoma. Immunotherapeutic 
approaches, aimed at triggering and/or restoring host immune system 
against the tumor, can be divided in two main groups: adoptive 
immunotherapy and vaccination or active specific immunotherapy. 
In adoptive immunotherapy, in vitro activated immune effector cells or 
specific antibodies are exogenously administered to patients.  
Conversely, cancer active immunotherapy mainly consists in therapeutic 
vaccines aimed at the induction of antibodies or T cell-mediated tumor 
specific immune responses. Final goal of active immunization is the 
generation of a long lasting immunological memory.  
 
 
 
 
 
 
 
 
                                                                                       Chiara Camisaschi 
 
14 
 
Table 2. Human melanoma antigens classification (Adapted from Novellino et al., 2005) 
Human melanoma antigens recognized by T cells 
 
Melanocyte lineage/differentiation antigens:  
shared between tumor and normal tissue,  
found in melanoma and melanocytes 
Tyrosinase           gp75                      
gp100                   TRP-2  
MC1R                  OA1 
PSA                      P Polypeptide 
MelanA-MART1 
 
Oncofetal/cancer-testis antigens:  
normally expressed in testis and  
placenta, re-activated in tumor 
MAGE family     CAMEL 
BAGE family      NA88-A 
GAGE family      SSX-2 
NY-ESO1            TRAG-3 
 
Unique and shared tumor-specific antigens:  
point mutations or splicing aberration of  
normal genes, often associated with  
neoplastic transformation and/or progression 
 
CDK-4                 BING-4 
β-catenin              N-RAS 
MART-2              TRP2 
Myosin                 ARTC-1 
MUM family 
 
Widely occurring overexpressed TAAs: 
universal antigens associated  
with tumorigenic phenotype,  
generally with lower expression in normal tissue 
 
Survivin               SART-2 
SOX10                 hTERT   
707-AP                 p15 
HER-2/neu           Adipophilin 
GnT-V                  Livin 
Epha2-3                PRAME 
AIM-2                  RAGE 
Annexin II           RU1-2 
 
 
 
1.3.3 Immune-based therapy in melanoma 
The most important therapeutic agent for melanoma treatment has been 
the T-cell growth factor IL-2. IL-2 exerts its function through its ability 
to expand and activate T and natural killer (NK) cells. Studies reported 
overall response rate of 15-20% with durable responses (Atkins et al., 
1999). In light of these findings IL-2 has been approved by the Food and 
Drug Administration (FDA) as treatment for metastatic melanoma, but 
the toxicities associated with high-dose IL-2 have been the main obstacle 
to its widespread use in the treatment of patients. In addition IL-2, 
extensively used in immunotherapy protocol to boost T effector cells 
Regulatory T cells in melanoma patients                                                  
 
15 
 
response, has been described to increase the frequency of circulating 
Tregs (Ahmadzadeh M et al., 2006). 
Interferons (IFN) are a complex family of proteins with 
immunomodulatory and antiangiogenic properties that are produced in 
response to viral infection or after T-cell activation. IFN-α has been the 
most extensively studied in melanoma. It produces responses in about 
16% of metastatic melanomas (Agarwala and Kirkwood, 1996). It has 
been used in combination with other agents, with higher response rates in 
the IFN-α containing regimens (Hwu et al, 2006). Currently, IFN-α is 
used for high risk melanoma patients to prevent recurrences (Ascierto and 
Kirkwood, 2008). However, the use of IFN-α is under debate since 
significant effects on overall survival are not confirmed and for its high 
toxicity and severe side effects. 
New immune-based strategy for melanoma is based on the in vivo usage 
of immunomodulating antibodies directed against molecules crucially 
involved in the fine tuning of the immune-response. These antibodies 
include those receptors that suppress the host immune response 
(Cytotoxic T-lymphocyte antige-4, CTLA-4 and Programmed Death-1, 
PD-1) and those that activate receptors that amplify the immune response 
(CD40 on antigen presenting cells (APC), CD137 and OX40 on T cell).  
Early clinical studies defined human anti-CTLA-4 antibodies 
(ticilimumab, iplimumab) pharmacokinetics and possibilities for 
combination therapeutic regimen. Phase II trials of ipilimumab in 
advanced melanoma showed objective responses and, in a phase III trial, 
ipilimumab was the first agent to demonstrate an improvement in overall 
survival (10.1 months) in patients with advanced melanoma. In 10-15% 
of the treated patient severe immune related adverse events occurred, but 
most this treatment-related toxicity was reversible with appropriate care 
(Hodi et al., 2010).  
As previously discussed, active immunotherapy mainly includes 
therapeutic vaccine whose final aims is the generation of a long lasting, 
tumor-specific immune response. Vaccines for melanoma are designed to 
boost immune reactions against a malignancy that is already established, 
aimed at activating or boosting host immune responses possibly inducing 
an endogenous immunity. The selection of suitable antigens is the first 
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decisive step in designing cancer vaccines; antigens should include 
molecules preferentially expressed by tumor tissues, in order to prevent 
cross-reaction with normal cells. Indeed, the majority of cancer antigens 
are represented by proteins preferentially expressed by tumor cells but 
still belonging to self and thus potentially subjected to tolerance 
(melanoma antigens classification is reported in Table 2). One major 
issue in vaccine design is therefore the selection of antigens which should 
induce tumor immunity without autoimmunity and antigen formulation is 
an additional crucial issue for achieving a successful immunization. 
Different vaccination modalities exist: cell-based vaccination using 
dendritic cells (DCs) loaded with antigens, protein/peptide vaccines, 
genetic vaccines (DNA or RNA encoding the antigen), viral vectors, or 
combination of these with or without adjuvant. Several studies have 
explored the efficacy of tumor-associated antigenic peptides with or 
without IL-2, DC or other adjuvant. However, despite the induction of 
tumor-specific immune responses induced by immunotherapy approaches 
can be observed in patients with melanoma, favourable clinical outcomes 
are scarce (Jandus et al., 2009).  
The first evidence of clinical benefit was reported recently in a 
randomized phase III clinical study in which melanoma patients received 
gp100 and high dose of IL-2 (Schwartzentruber et al., 2009).  
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2. IMMUNOEDITING THEORY 
The encounter between the immune system and a newly generated tumor 
develops through a process known as “immunoediting”, in which three 
distinct phases can be defined (Dunn et al., 2002): 
- eradication of cancer, in which cells of the innate and adaptive 
arms of the immune system are recruited following a “danger” signal 
generated from newly growing tumors (Gallucci and Matzinger, 
2001); 
- cancer equilibrium, a condition in which the host immune system 
and any tumor cell variant, survived the eradication phase, enter into 
a dynamic equilibrium: tumor cells are continuously eliminated, but 
the immune selection pressure induce the production of resistant 
tumor variants (Koebel et al., 2007). Equilibrium is probably the 
longest phase of cancer immunoediting, and it may last several years. 
- tumor escape, that is the ability of tumor to growth despite 
activation of the immune system. This may be achieved through a 
variety of mechanisms that the tumor itself has developed to evade 
immune recognition and attack (Rivoltini et al., 2005). 
 
2.1 Immune escape mechanisms 
1) Loss or down-regulation of MHC class I expression on tumor 
cells 
Down-regulation of major histocompatibility (MHC) class I 
proteins prevents the formation of MHC/peptide complexes necessary for 
cytotoxic T lymphocytes (CTL) recognition, therefore inhibiting 
cytotoxic T cell-mediated lysis (Chang and Ferrone, 2007). 
2) Impairment of antigen recognition 
Tumors may develop defective antigen processing pathways, 
thanks to mutations in genes coding for molecules crucial for antigen 
presentation or peptide transport to the endoplasmic reticulum, as the 
case of TAP (transporter associated with antigen presentation). When 
such mutations occur, tumor-associated antigens, although present, 
cannot be presented by MHC molecules, therefore allowing progression 
of the disease (Maeurer et al., 1996).  
3) Inactivation of final effector functions of immune cells  
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Using different mechanisms, tumor cells may directly limit the function 
of the immune effector cells. Examples are the impaired binding of 
perforin molecules released by CTL to the surface of tumor cells, that 
became resistant to perforin-mediated killing (Lehmann et al., 2000); or 
down-regulation or mutations of Fas gene, leading to breakdown of 
Fas/FasL pathway (French and Tschopp, 2002). 
4) Tolerance induction 
Tumors can also activate mechanisms that directly impair   
immune responses and lead to tolerance. First, lack of costimulatory 
molecules (B7-1/CD80, B7-2/CD86, and CD40L) or activation of 
negative costimulatory signals (CTLA-4/B7, PD-1/PD-L1, Fas/FasL) can 
prevent activation of CTL, leading to clonal anergy of tumor-specific T 
cells (Gajewski, 2007). Moreover, pre-existing functionally activated 
CTL may become anergic in the absence of DC-activating signals 
(Staveley-O’Carroll et al., 1998) or in the presence of tolerogenic DC, 
such as plasmacytoid DC (pDC), which inhibit effector T cells 
proliferation by 2,3-dioxigenase (IDO) production (Puccetti and 
Grohmann, 2007). Tumors can also down-regulate the expression of 
endothelial adhesion molecules, thus reducing the homing of T cells at 
tumor site (Madhavan et al., 2002).  
5) Active immunosuppression 
Apart from inducing tolerance, tumors can also actively suppress immune 
responses either systemically or in their microenvironment.  
One of the most frequent mechanisms adopted by tumors to actively 
suppress immunity relies on the secretion of a variety of soluble 
immunosuppressive factors, such as TGF-β (Teicher, 2007), IL-10 
(Kawamura et al., 2002), nitric oxide (Zhang and Xu, 2001), galectin-1 
(Danguy et al., 2002) and prostaglandin-E2 (PGE2). Tumors also induce 
accumulation of activated granulocytes (Schmielau and Finn, 2001), mast 
cells (Conti et al., 2007), tumor-associated macrophages (TAMs) 
(Mantovani et al., 2011) and the generation of a subset of inflammatory 
monocytes, so-called myeloid-derived  suppressor cells (MDSC), which 
strongly inhibit CD8+ T cell responses, NK activity and DC maturation 
(Filipazzi et al., 2007). Moreover, the presence in the tumor 
microenvironment of tolerogenic subpopulations and the abundant 
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expression of cytokines and chemokines such as TGF-β, IL-10, 
chemokine (C-C motif) ligand 2 (CCL2), CCL17, CCL22, or IDO 
contribute to regulatory T cells (Tregs) accumulation and differentiation 
within the tumor mass and in the draining lymph nodes (LNs) (Curiel et 
al., 2004; Beyer and Shulze, 2006).Together with tolerogenic DC, Tregs 
inhibit the generation of effector T cells, resulting in the induction of 
tolerance against the tumor (Figure 1).   
 
 
 
Figure 1. Treg accumulation at tumor site. Tregs expressing CCR4 are attracted at 
tumor site by the presence of chemokines as CCL2 and CCL22 (A). Factors released by 
tumor or tolerogenic APC in tumor microenvironment can induce Treg conversion and 
proliferation (B and C). Tregs induce effector T cells apoptosis and block their 
proliferation (D). (Adapted from Jacobs et al., 2012). 
 
 
2.2 TREGs  
Tregs, that comprise 5-10% of peripheral CD4+ T cells in humans, have 
an essential role in sustaining self-tolerance and immune homeostasis by 
suppressing many physiological and pathological immune-responses 
(Sakaguchi et al., 2008). Their development and function depends on the 
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nuclear transcription factor forkhead box P3 (Foxp3) and mutations in 
this gene cause fatal autoimmune diseases (Sakaguchi et al., 2008). 
 
2.2.1 Treg subsets 
Tregs consist of different subsets of cells that can be identified on the 
basis of their origin and mechanism of immune suppression (Roncarolo et 
al., 2000). Induced Tregs include Tr1 and Th3 CD4+ T cells. Tr1 cells 
arise from CD4+ T cells in a tolerogenic environment and secrete high 
level of IL-10; while Th3, which are induced by oral Ag administration, 
secrete high level of TGF-β. On the other hand, naturally occurring 
CD4+ Tregs, that constitutively express the interleukin-2 (IL-2) receptor 
alpha-chain (CD25) and Foxp3, are produced by the normal thymus as a 
functionally distinct and mature subpopulation of T cells (Jonuleit et al., 
2003). Tregs can be also induced in the periphery from naïve T cells 
under certain condition (Akbar et al., 2007). 
 
2.2.2 Mechanisms of suppression  
The mechanisms by which Tregs mediate immune suppression are not 
completely elucidated, but are likely to include both cell-cell contact and 
cytokine secretion (Zou et al., 2006). 
Natural Tregs, upon T cell receptor (TCR) engagement (Baecher-Allan et 
al., 2004) exert their suppressive functions in a contact-dependent 
fashion. However, Tregs act with different mechanisms and, based on 
their mode of action, Tregs can be further classified into discrete subsets 
that differently rely on cell to cell contact and on IL-10 secretion (Ito et 
al., 2008). Furthermore, the fine mechanism of action of TGF-β, an 
additional cytokine well accepted crucially involved in Treg suppression, 
has not been sort out completely. 
Some Tregs are antigen specific (Tang et al., 2008), but once activated 
they can also suppress by an antigen-independent bystander mechanism 
(Tang et al., 2008).  
In line with these observations, it has been clearly demonstrated that 
antigen-specific Tregs actively suppress proliferation of CD4+CD25- and 
CD8+ effector T cells in most human solid tumors as well as hematologic 
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malignancies, therefore limiting the immune response against cancer and 
contributing to tumor progression (Piersma et al., 2008). 
 
2.2.3 Tregs in tumors 
The significant role of CD4+ Tregs in suppressing anti-tumor immune 
response has been well documented for murine tumors (Sakaguchi et al., 
2004). However, in humans the possible implication of CD4+ Tregs in 
down-modulating anti-tumor immunity is under intense investigation. A 
number of studies have reported an increase in circulating CD4+ Tregs in 
patients with various cancers (Viguier et al., 2004; Curiel et al., 2004; 
Woo et al., 2001). Furthermore, increased percentages of Tregs in the 
peripheral blood of gastric and esophageal cancer patients and in the 
tumor tissue correlated with poor prognosis and decreased survival 
(Curiel et al., 2004; Kono et al., 2006).  
 
2.2.4 Tregs in melanoma  
 As compared with age matched healthy control, Tregs are 
overrepresented in peripheral blood of melanoma patients (Correll et al., 
2010; Jandus et al., 2008; McCarter et al., 2007), in primary lesion 
(Ladanyi et al., 2010; Miracco et al., 2007), tumor invaded LNs (Jandus 
et al., 2008) and metastatic lesions (Mourmouras et al., 2007; 
Ahmadzadeh et al., 2008). Moreover, several studies reported a 
correlation between the extent of Tregs infiltration and prognosis in 
patients with melanoma, but results are contradictory in literature and 
often this correlation was not found (Ladanyi et al., 2010; Lagouros et al., 
2009). 
 
2.2.5 Treg depletion  
Treg mediated immune-suppresion is one of the main obstacle for cancer 
immunotherapy. Depletion of Tregs in murine model of melanoma leads 
to enhanced induction of anti-tumor immunity and to an improvement in 
tumor clearance and survival (Nizar et al., 2010); so, Treg depletion is 
under intense investigation also in humans. There are different 
approaches aimed at depleting Tregs or blocking their activity. To date 
the main strategies adopted in clinical trials include the usage of 
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molecules targeting CD25 or the administration of Cyclophosphamide 
(N, N-bis (2-chloroethyl)-1, 3, 2- oxazaphosphinan -2 amine 2-oxide, the 
generic name for Cytoxan (CTX), Endoxan). Jacobs and colleagues 
achieved systemic depletion of CD25 positive cells with anti-CD25 
antibody (daclizumab) in metastatic melanoma patients before the 
administration of a peptide-pulsed DC vaccine. This antibody treatment 
however did not lead to any increase in the extent of tumor-specific 
immune response and had no effect on progression-free survival (Jacobs 
et al., 2010). Conversely, depletion of CD25+ cells using the clinically 
approved IL-2 diphtheria toxin conjugated (Ontak) showed clinical 
responses when combined with vaccination in mice and colon cancer 
patients (Knutson et al., 2006; Dannull et al., 2005), but the same 
schedule applied to melanoma patients provided  contradictory results 
(Mougiakakos et al.,  2010; Attia et al., 2005). Of note, CD25 is also 
expressed on activated non-regulatory T cells and therefore 
administration of anti-CD25 antibodies could possibly limit also positive 
anti-tumor responses.  
The alkylating agent CTX has a broad spectrum of action. It is used to 
treat vary types of diseases: solid and hematological malignancies, 
autoimmune disorder and transplantations. CTX reduces the number of 
circulating Tregs in animal models (Ghiringhelli et al., 2004; Lutsiak et 
al., 2005), but the same result in human has not been clearly 
demonstrated. The biological activities of CTX are dose dependent and 
the metronomic dosing, in combination with others therapies, has 
immunomodulatory and antiangiogenic attributes (Sistigu et al., 2011; 
Ghiringhelli et al., 2007).  
Actually why CTX has these positive effects is not totally understood. 
CTX seems to have a complex role; in fact, it can act not only on 
proliferating tumor cells, but also on the different cell types composing 
the immune system. In addition, the study of this molecule is difficult due 
to its transient effect.  
 
2.2.6 Treg heterogeneity and plasticity 
The contradictory results about Treg monitoring are mainly due to the 
fact that most of the studies are retrospective and the exact definition of 
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Tregs and the techniques of Treg analyses greatly affect the result of Treg 
measurements.  
Naturally occurring Tregs in mice are unequivocally defined as 
CD4+CD25+Foxp3+ T cells. This same set of markers, together with low 
level expression of IL-7 receptor alpha (CD127) (Seddiki et al., 2006), 
identifies also human Tregs, but recent studies have clearly indicated that 
new hallmarks of Treg phenotype need to be identified, being 
CD4+CD25+Foxp3+ expression shared also by effector T cells in humans. 
A more accurate analysis of human Tregs combining CD4, CD25, Foxp3 
and CD45RA allows to identify different subsets of human Tregs and 
differentiate them from conventional activated T cells (Myiara et al., 
2009). Furthermore, a part of molecules constitutively expressed by 
human Tregs such as CTLA-4, GITRL, CD27, CD28, OX40 and CD62L, 
the expression of molecules as MHC-class II, CCR7, CD147, CD39, 
GARP and co-stimulatory molecule as ICOS (Tosello V et al., 2008; 
Baecher-Allan C et al., 2006; Ito T et al., 2008; Solstad T et al., 2011; 
Borsellino et al., 2007; Tran et al., 2009) identifies different Treg subsets, 
highlighting the wide heterogeneity of these populations. In addition, 
recent studies provide evidence not only for functional heterogeneity, but 
also for high lineage plasticity of Tregs. They can indeed differentiate 
into IL-17 producing Th17, acquiring RORγt expression with or without 
losing Foxp3 expression (Bovenschen, et al., 2011; Raffin et al., 2011). 
Moreover, human Tregs cultured in vitro in the presence of IL-12 acquire 
a Th1 phenotype secreting IFNγ and expressing T-bet without the loss of 
Foxp3 expression (Dominguez-Villar M et al., 2011).  
 
Different techniques to identify Tregs: 
- immunohistochemistry: not the better way to identify Tregs since 
only a small number of Treg markers can be used, but it allows to 
visualize Tregs within the tissue contest and it can be useful for 
retrospective studies 
- Treg quantification by methylation-specific quantitative PCR: it 
enables naturally occurring Tregs to be distinguished from 
activated T cells; in fact it has been recently demonstrated that 
Tregs possess a demethylated conserved region in the FOXP3 
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intron 1 that is completely methylated in other human cells of 
hematopoietic origin, even after activation (Zheng et al., 2010). 
- multicolor flow cytometry: lacking an unique Treg specific 
marker to define Tregs, the combination of different markers are 
required to distinguish Tregs from activated T effector cells. 
Notably, this multiparametric Treg definition allows the 
combination of additional markers aimed at defining the 
functional properties of the different Treg subsets combining 
activation, homing and functional markers. It also allows Treg 
sorting, either to assess Treg suppressor activity in vitro or to 
further characterize them with microarray or mass spectrometry 
analysis. 
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3. LYMPHOCYTE ACTIVATION GENE-3 (LAG-3): A KEY 
REGULATOR OF THE IMMUNE RESPONSES 
 
3.1 Basic concepts 
Human LAG-3 was initially identified as a member of the 
immunoglobulin superfamily (IgSF) (Triebel et al., 1990) selectively 
transcribed in human activated T lymphocytes and NK cells. Early 
studies were focused on the analysis of gene sequence and protein 
structure and a close homology between LAG-3 and CD4 was found, thus 
suggesting the possibility that these two molecules did share common 
ligands. Now it is well known that LAG-3 is a physiological ligand of 
MHC class II and works as a key regulator of T cell homeostasis and also 
as a powerful activator of antigen presenting cells (Triebel, 2003). 
 
3.2 Biology of LAG-3  
3.2.1 Structure of human LAG-3 gene and protein  
Human LAG-3 gene is located on the distal part of the short arm of 
chromosome 12 (12p13.3), close to CD4 gene (Barten et al., 2001). LAG-
3 gene is made up of eight exons that span 6 kb; the corresponding 
mRNA (a 2-kb message) encodes for a 498-amino acid protein (70 kDa 
weight) composed by 4 extracellular IgSF domains, a trans-membrane 
domain (TM) and a short cytoplasmic tail (Cyt) (Figure 2 A).  
LAG-3 gene in mouse shares strong homology with its human 
counterpart. The cytoplasmic tail of the protein contains three different 
regions conserved between mouse and human LAG-3. The first motif is a 
potential serine phosphorylation site, resembling the protein kinase C 
binding site in CD4. The second is a conserved KIEELE motif with no 
homology to any other known protein. The third motif is an unusual 
glutamic acid-proline (EP) repetitive sequence. 
In humans, an alternative splicing of LAG-3 RNA just following exon 5 
causes the generation of a truncated form of the protein, termed LAG-
3V3 (for LAG-3 variant 3) (Figure 2 B); this 52 kDa variant, lacking both 
the trans-membrane and cytoplasmic domains, represents a natural 
soluble form of the protein and was indeed found in sera of healthy 
individuals after T cell activation (Annunziato et al., 1996). The natural 
                                                                                       
 
soluble form is present also in tuberculosis and breast cancer patients’ 
sera at high level (Triebel et al., 2006).
 
 
Figure 2. Organization of LAG-3 protein. 
extracellular IgSF domains. The intra-cytoplasmic KIEELE and repeated EP motifs are 
indicated. Dashed line indicate the site of cleavage
LAG-3V3 protein found in human serum. (B). Abbreviations: Trans
(TM) and Cytoplasmic tail (Cyt). (Adapted from Huard et al., 1994).
 
 
3.2.2 Molecoular proprieties 
CD4 and LAG-3 share common ligand, namely 
complex (MHC) class II molecules (Huard et al., 1997) but, notably, 
LAG-3 binds MHC class II with higher affinity than CD4. The MHC 
class II binding site of LAG-3 is located in the N
probably involves the 30-aa extra-loop sequence found in dom
same domain contains a second binding site for another LAG
allowing the assembly of homodimers on the cell surface. Yet it is not 
clear if the oligomerization process is constitutively activated or induced 
after a transient interaction with MHC class II molecules, as in the case of 
CD4.  
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Structure of LAG-3 protein: D1-D4, 
 (A). Structure of natural soluble 
-membrane domain 
 
major histocompatibility 
-terminal region and 
ain D1, the 
-3 molecule, 
Regulatory T cells in melanoma patients                                                  
 
27 
 
MHC class II uses two alternative regions for its binding with LAG-3 and 
CD4, implying that LAG-3 and CD4 do not compete for their access to 
MHC class II (Huard et al., 1997).  
Half the cellular content of LAG-3 is retained in intracellular 
compartments. This significant intracellular storage of LAG-3 and its 
close association with the microtubule organizing center and recycling 
endosomes appears to facilitate its rapid translocation to the cell surface 
following T-cell activation (Woo et al., 2010). LAG-3 cell surface 
expression is in fact tightly regulated by extracellular cleavage and two 
metalloproteases, namely ADAM10 and ADAM17, are responsible of the 
cleavage (figure 2).  
 
3.2.3 Expression pattern and cellular localization of LAG-3 protein  
Identification and first characterization of LAG-3 were performed in 
early 1990s. Human LAG-3 protein was found to be specifically 
expressed in activated CD4+ and CD8+ T lymphocytes and NK cells 
(Triebel et al., 1990). In humans rare LAG-3+ cells were detected in 
primary (adult thymus and bone marrow) and secondary (spleen and 
MALT) lymphoid organs, while no expression could be found in non 
lymphoid organs (Huard et al., 1994a); conversely, high levels of LAG-3 
were found in inflamed tonsils and lymph nodes with follicular 
hyperplasia. LAG-3 expression was also observed in CD8+ tumor 
infiltrating lymphocytes (TIL) infiltrating various types of cancer (renal 
cell carcinoma, melanoma, lymphoma and ovarian cancer) (Demeure et 
al., 2001; Matsuzaki et al., 2010).  
All together these data led to the definition of LAG-3 as a lymphocyte 
activation antigen broadly expressed and not restricted to a unique subset 
of cells.  
 
3.3 LAG-3 functions 
3.3.1 The enigmatic role of LAG-3 in the immune system: costimulatory 
or inhibitory molecule? 
The physiological role of LAG-3 has remained elusive. However, recent 
evidences have now clearly revealed that this molecule plays a dual role 
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in the immune system, acting either as a negative regulator of activated T 
cells or as an activator of APC.  
 
3.3.2 LAG-3 as a negative regulator of T cells 
Studies on human activated T cells demonstrated that LAG-3 can act as a 
negative modulator of T cell functions. Thus, when LAG-3/MHC class II 
interactions were inhibited, a strong increase in T cell proliferation and 
cytokine secretion was induced, while its overexpression or the inhibition 
of its surface cleavage led to impaired antigen driven T cell proliferation 
without inducing T cell death (Li et al., 2007).  When triggered by 
encounter with its nominal antigens, namely MHC-class II, LAG-3 
induces down-modulation of TCR/CD3 and affects proximal TCR 
signaling, leading to T cell unresponsiveness and to the inhibition of 
TCR-induced calcium fluxes (Hannier et al., 1998), lower IL-2 
production and reduced production of Th1 type cytokines (Huard et al., 
1994).  
LAG-3 signaling could induce in activated T cells a refractory state 
necessary to prevent undue activation without a proper TCR triggering; 
this inhibition of T cell expansion may be obtained by preventing the 
entry of T cells through the S-phase of cell cycle (Maçon-Lemaître and 
Triebel, 2005). LAG-3 might therefore act as a negative regulator by 
limiting the rate of cell division. 
Recent studies in mouse model have highlighted the fact that exhausted 
CD8+ T cells following chronic viral infections express multiple 
inhibitory receptors such as PD-1. Among these inhibitory coreceptors, 
LAG-3 was observed to be expressed at high level during chronic viral 
infections; the simultaneous in vivo blockade of the PD-1 and LAG-3 
inhibitory receptor pathways  led to a strong reversal of T cell exhaustion 
and viral control indicating a synergy between this two negative co-
receptors (Blackburn et al., 2009). In humans, coexpression of PD-1 and 
LAG-3 was observed in tumor infiltrating NY-ESO1 specific CD8+ T 
cells in patients with ovarian cancer, the two molecules indentify a 
subpopulation of T cells with diminished capacity to produce IFN-γ and 
tumor necrosis factor alpha (TNF-α); also in this case only the dual 
Regulatory T cells in melanoma patients                                                  
 
29 
 
blockade of LAG-3 and PD-1 increased T cell frequency and IFN-γ 
production (Matsuzaki et al., 2010). 
Not surprisingly, being a molecule belonging to the inhibitory co-
receptors group, such as CTLA-4 and PD-1, LAG-3 has been recently 
described in mice as a novel CD4 and CD8 Treg-associated marker that is 
directly involved in the control of T cell expansion and homeostasis 
(Huang et al., 2004; Grosso et al., 2007). Recent data in humans 
identified a new subset of CD8+ Tregs expressing LAG-3 that mediate 
immunosuppression via the secretion of CCL4 (Joosten et al., 2007). 
Moreover, there is evidence of its involvement in tumor-infiltrated CD4+ 
Treg function in Hodgkin’s lymphoma (Ghandi et al., 2006). Importantly, 
LAG-3 expressed by human Tregs seems to play a functional role; in fact 
the interaction between LAG-3 and MHC class II molecules is involved 
in the functional inhibition of DC activation by Tregs (Bayry et al., 
2007).  
All together these findings strongly highlight the role of LAG-3 as 
molecule crucial in immune homeostasis and in the fine tuning of T cell 
activation. 
 
3.3.3 LAG-3 as an APC activator  
The majority of studies aimed at evaluating the effect of LAG-3 binding 
to MHC class II and its functional role on the transduction of signals into 
APC has been conducted by using a recombinant soluble form of the 
protein, termed LAG-3Ig. APC expressing high levels of MHC class II 
molecules tightly bind LAG-3Ig (Andreae et al., 2002) and this binding 
induces DC maturation, as detected by release of pro-inflammatory 
cytokines and chemokines able to direct their migration to secondary 
lymphoid organs (Andreae et al., 2002; Buisson and Triebel, 2003); in a 
physiological context, LAG-3 expressed on activated CD4+ T cells and 
able to bind class II-associated peptides may license DC to efficiently 
present class I-restricted peptides to CD8+ T cells (Machy et al., 2002). 
In this regard our laboratory showed that LAG-3 when expressed on 
activated CD4+ T cells functions as a costimulatory molecule and in 
association with CD40/CD40L induce a full functional activation of DC 
(Casati et al., 2006; Casati et al., 2008). 
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Significant levels of LAG-3 protein have been found on the surface of 
lymphocytes infiltrating various types of tumors (Demeure et al., 2001); a 
positive direct role of LAG-3 expressed on these TIL in the engagement 
of class II molecules on APC has been described, thereby contributing to 
APC activation and Th1/Tc1 commitment.  
So, LAG-3 is a two-way signaling molecule: when triggered it transduces 
an inhibitory signal inside the T cells, while promoting maturation and 
full activation of the APC  bearing its natural ligand, MHC class II 
(figure 3).  
 
 
 
 
 
 
Figure 3. Interactions between LAG-3 and MHC class II molecules. 
Schematic representation of different functional roles of LAG-3 protein through the 
interaction with MHC class II molecules (adapted from Triebel et al., 2003). 
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MAIN RESULTS 
 
“Lymphocyte Activation Gene-3 Expression Defines a Subset of 
CD4+CD25highFoxp3+ Regulatory T Cells That are Expanded at Tumor 
Sites”. (Paper at page 64) 
 
Studies in mice indicated that LAG-3 has a complex role in T cell 
homeostasis and is expressed by CD4+CD25+ Tregs. By the usage of 
multiparametric FACS analysis, I explored the distribution of LAG-3 in 
human CD4+ T cells. LAG-3 was found to define a discrete subset of 
CD4+CD25highFoxp3+ T cells, indeed cells with a Treg phenotype 
(figure 1). 
To investigate whether this CD4+CD25highFoxp3+LAG-3+ population 
were expanded in advanced melanoma patients, I analyzed their presence 
in PBMCs, LNs and visceral metastasis of patients with stage III and IV 
melanoma. I found that this Treg subset expressing LAG-3 is expanded in 
patients’ PBMCs and this expansion was even more evident in 
lymphocytes of tumor-invaded as compared to tumor- free LNs and in 
lymphocytes infiltrating visceral and sub cute metastasis (TIL) (figure 2).  
These cells were further characterized for the expression of CCR7 and 
CD45RA; as expected, both LAG-3- Tregs and LAG-3+ Tregs included 
effector memory T cells (CD45RA-CCR7-), while terminal effector T 
cells were preferentially found as part of the LAG-3+ Tregs (figure 3).   
The ex-vivo functional analysis performed by FACS and intracellular 
cytokine staining confirmed that CD4+CD25highFoxp3+LAG-3+ were 
functionally active cells that released the immunosuppressive cytokines 
IL-10 and TGF-β1. These cytokines are involved in mediating Treg 
function. Of note CD4+CD25highFoxp3+LAG-3+ T cells did not produce 
IL-2, excluding the possibility that CD4+CD25highFoxp3+LAG-3+ cells 
were recently activated conventional effector T cells.  Comparing LAG-
3+ Tregs to LAG-3- Tregs, the association between LAG-3+ Tregs and 
the production of immunosuppressive cytokines was also observed in 
melanoma patients’ PBMCs and tumor-invaded LNs (figure 4). 
In addition to produce cytokines, Tregs inhibited the proliferation of 
CD4+CD25- T cells by direct contact. Thus an in vitro suppression assay 
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was set up. CD4+CD25highLAG-3+ T cells were sorted from in vitro 
expanded CD4+CD25high Tregs and they suppressive capacity assessed in 
an inhibition assay and compared with that of the LAG-3- counterpart. 
Interestingly, the LAG-3+ subset resulted more suppressive than the 
LAG-3-/low subset (figure 5). Suppression experiments were also 
performed in transwell plates and in the presence of anti-IL-10 and anti-
TGF-β1 neutralizing mAbs; data showed that LAG-3+ Tregs exerted 
their suppressor activity mainly via direct cell-to-cell contact, because the 
prevention of a physical interaction between LAG-3+ Tregs and CD25- 
responder T cells completely restored their proliferative capacity (figure 
6). 
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CONCLUSIONS 
 
 
PHENOTYPICAL CARACHTERIZATION: 
 
1) LAG-3 is preferentially expressed by regulatory 
CD4+CD25highFoxp3+ T cells and defines a discrete subset of 
CD4+CD25highFoxp3+ T cells in PBMCs of healthy donors (figure 
1) 
 
2) Cancer patients show increased frequency of 
CD4+CD25highFoxp3+LAG-3+ T cells in PBMCs, LNs and TIL of 
cancer patients (figure 2) 
 
3) CD4+CD25highFoxp3+LAG-3+ T cells display phenotypic features 
of effector-memory and terminal effector T cells (figure 3) 
 
 
FUNCTIONAL CARACHTERIZATION: 
 
4) CD4+CD25highFoxp3+LAG-3+ T cells produce IL-10 and TGF-β1 
cytokines (figure 4) 
 
5) CD4+CD25+LAG-3+ T cells are highly suppressive in vitro 
(figure 5) and need cell-to-cell contact (figure 6) 
 
 
 
 
 
 
All together, these data show that LAG-3 defines a  functionally active 
CD4+CD25highFoxp3+ regulatory T cell subset whose frequency is 
enhanced in melanoma patients, especially in tumor invaded LNs and at 
tumor sites. 
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Figure 1  
A) FACS gating strategy: Tregs belong to the CD4+CD25high subpopulation and are 
positive for Foxp3 expression. 
 
B) In healthy donors’ PBMCs, Foxp3 uniformly stained all the CD4+CD25high T 
cells, while LAG-3 expression defined a discrete subset of T cells inside the 
CD4+CD25highFoxp3+ compartment.   
A 
B 
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Figure 2  
A) Percentage of LAG-3+Foxp3+ cells in CD4+CD25high T cells was significantly 
increased in melanoma patients’ (Pt) PBMCs if compared to healthy donors (DON).  
 
B) Frequency of LAG-3+Foxp3+ in CD4+CD25high T cells was significantly higher 
in lymphocytes from tumor-invaded lymph nodes (LN TUM+) and tumor infiltrated 
lymphocytes (TIL) from visceral and sub cute metastases compared with those of 
tumor-free lymph nodes (LN TUM-). 
 
A 
B 
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Figure 3 
A) Gating strategy to define the in vivo differentiation stage of LAG-3- and LAG-3+ 
CD4+CD25highFoxp3+ T cells based on their percentage distribution in naïve (N), 
central memory (CM), effector memory (EM) and terminal effector (TE).  
 
B) Melanoma patients’ LAG-3- Tregs and LAG-3+ Tregs displayed features of 
effector memory cells and a small fraction of LAG-3+ Tregs showed also a terminal 
effector phenotype. 
 
A 
B 
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Figure 4 
A) Healthy donors’ PBMCs were activated with anti-CD3/CD28 beads and 
analyzed for intracellular production of the immunosuppressive cytokines IL-10 
and TGF-β1. These cytokines were only present in the CD4+CD25highFoxp3+ 
fraction and were mainly produced by LAG-3+ subset. Intracellular expression of 
IL-2 was detectable only in the CD4+CD25low compartment.  
 
B) The same analysis comparing the intracellular cytokine production in patients’ 
PBMCs (PT) and LNs showed that IL-10 and TGF-β1 production was increased in 
LAG-3+ Tregs. 
 
A 
B 
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Figure 5 
% proliferation of autologous CD25- T cells (Teff) was evaluated with 
[3H]thymidine incorporation assay or carboxyfluorescein succinimidyl ester (CFSE) 
labeling, after 3-5 days of co-culture with Tregs in the different conditions reported. 
Sorted LAG-3+CD25+  Sorted LAG-3-/lowCD25+ 
LAG-3+CD25+ and LAG-3-/lowCD25+ T cells were FACS sorted from in vitro 
expanded CD4+CD25+ lymphocytes and used as suppressor cells in a inhibition 
assay. The capacity to suppress proliferation of autologous CD25- T responder cells 
resulted markedly higher for LAG-3+ Tregs. 
Inhibition assay 
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Figure 6 
LAG-3+ Tregs exert their suppressor activity mainly via a direct cell-to-cell contact, 
because prevention of physical interaction with transwell plate between Tregs and 
Tresp completely restored Tresp proliferation. The addition of anti-IL-10 and anti-
TGF-β1 neutralizing mAbs did not affect the inhibitory activity of LAG-3+ Tregs. 
Treg = CD4+CD25+LAG-3+ sorted T cells 
Tresp = CD4+CD25- freshly isolated autologous T cells 
 
Rato 1:1 
Lower 
Chamber 
Upper 
Chamber
Med plus IgG 
or Abs
TRANSWELL PLATE
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MAIN RESULTS 
 “Frequency and function of circulating regulatory T cells in melanoma 
patients receiving peptide-based vaccine”. (Manuscript at page 72) 
 
Purpose: Tregs exert a detrimental effect on tumor immunity.  My thesis 
evaluated the influence of low-dose cyclophosphamide (CTX), low-dose 
IL-2 and peptide vaccination on the frequency and functional behavior of 
Tregs of melanoma patients and the impact of Tregs on antigen-specific 
response. 
Trial design: Phase II randomized study in HLA-A*0201 patients with 
melanoma (stage IIB/C-III): the study includes a vaccination and an 
observation arm. In the vaccination arm, patients received vaccination 
with  HLA-A*0201 tumor peptides, low dose of CTX (300 mg/m2 i.v.) as 
potential Treg-depleting agent and two injections of low dose IL-2 (3x106 
IU) to boost vaccine induced immune-responses. Blood samples were 
serially collected at different time points from patients enrolled in the 
study (vaccination arm n=16, observation arm n=19) (Figure 1, 
Schematic representation of vaccine schedule). In the control arm, 
patients received no treatment beside surgery.  
Results: Tregs defined as CD4+CD25highFoxp3+ were analyzed by FACS 
in PBMCs of vaccinated melanoma patients and compared to Tregs in 
control patients. As compared to pre-treatment, frequency of 
CD4+CD25highFoxp3+ Tregs shows a slight decrease in PBMCs collected 
4-7 days after CTX administration (P1 versus P0). However, this 
reduction was transient and although patients received additional CTX, 
the frequency of Tregs regained the original pre-treatment level (P4). 
Instead, low dose IL-2 induced a significant expansion of 
CD4+CD25highFoxp3+ Tregs (P6) (figure 2). 
To evaluate whether Tregs expanded by IL-2 administration were 
endowed with suppressive activity, an in vitro suppression assay was 
assessed. CD4+CD25high T cells isolated from PBMCs of a vaccinated 
patient at P6 of the vaccination were coltured in the presence of 
autologous CD4+CD25- T cells obtained at P0. Data indicate that low 
dose of IL-2 expanded Tregs functionally active, since proliferation of 
conventional CD4+CD25- cells was strongly inhibited (figure 3). 
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To further characterize these cells, the CD45RA marker was added in the 
multiparametric FACS analysis; in fact, in combination with CD25, it 
enables to discriminate between activated CD4+ Tregs 
(CD25highFoxp3+CD45RA-) and conventional activated CD4+ T cells 
(CD25intFoxp3intCD45RA-). Data confirmed that IL-2 boosted activated 
Tregs (Fr.b), but at the same time also conventional activated CD4+ T 
cells were augmented (Fr.a) (Figure 4). Activated T cells and Tregs pre 
and post IL-2 administration were characterized ex-vivo for the 
expression of two Th1 markers: T-bet (a transcription factor crucial for 
CD4+ Th1 commitment) and IFN-γ (the hallmark of Th1 cytokine). In 
activated conventional T cells, increase in T-bet positive cells paralleled 
the increase in the percentage of T cells producing IFN-γ. Thus these data 
support the conclusion that IL-2 may also expand activated CD4+ T cells 
producing Th1 related cytokines. Surprising enough T-bet and IFN-γ 
were also present and boosted after IL-2 administration in the fraction of 
activated Tregs, indicating a strong plasticity of Tregs that probably may 
acquire a Th1 phenotype in a pro-inflammatory environment (figure 4). 
To investigate the impact that Tregs exerted during the vaccination on 
antigen-specific CD8+ T cells, monitoring of peptide-specific, vaccine-
induced T cells was performed ex-vivo by HLA-A*0201/peptide 
pentamer staining. Results indicated that, the percentage of CD8+ 
pentamer positive cells increased after the second vaccination and was 
further boosted after IL-2 administration. Thus the raise in Tregs induced 
by IL-2 was not limiting the expansion of antigen-specific T cells (figure 
5). Moreover, in order to assess whether Tregs were negatively affecting 
the functional activity of antigen-specific CD8+ T cells, an IFN-γ 
ELISpot assay was performed. Data reported for two patients indicated 
that although IL-2 administration led to strong increase in Treg 
frequency, the number of CD8+ T cells producing IFN-γ in response to 
antigenic peptide stimulation remained stable or was further increased 
(figure 6). 
The same experiments were done in parallel with control patients’ 
PBMCs; Treg modulation during the vaccine course was never observed 
in these patients. 
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CONCLUSIONS 
 
Effect of CTX: 
 
1) Low dose CTX has a limited efficacy in modulating Treg 
frequency in vaccinated patients’ PBMCs and Tregs regain the 
original pre-treatment level in few weeks (figure 2) 
Effect of IL-2: 
 
2) Low dose of IL-2 strongly boosts the number of circulating 
CD4+CD25highFoxp3+ Tregs (figure 2) 
3) Low dose IL-2 directly affects Treg homeostasis by inducing an 
expansion of suppressive Tregs (figure 3) 
4) Low dose IL-2 expands both circulating conventional activated 
CD4+ T cells and Tregs; a fraction of these Tregs displays a Th-1 
like phenotype, expressing ex-vivo T-bet and INF−γ (figure 4) 
5) IL-2 induced Treg boosting is not hampering the vaccine induced 
immunity (figure 5)  
 
 
The results of this study indicate that CTX has only a limited efficacy in 
modulating Tregs. Instead there are clear evidences that low dose of IL-2 
given in a vaccination setting, although expanding Tregs, does not 
produce detrimental effect on the expansion and functional activities of 
antigen-specific CD8+ T cells induced by vaccination. Probably the 
balance among the different functional T cell subsets amplified by IL-2 is 
most likely influencing the immunological and clinical outcome of the 
vaccinated patients. 
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VACCINE SCHEDULE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  
V= peptide vaccine made of HLA-A*0201-restricted (Melan-A/MART-1[27L], 
gp100[210M], NY-ESO-1[165V], and Survivin[97M]) 250 µg each, emulsified in 
Montanide ISA-51  
 
CTX= Cyclophosphamide i.v. 300mg/m2  
 
IL-2 s.c. 3x106 IU/day for three daily injections 
 
P= blood samples collected (P0 = pre treatment; P1= after 1 dose of CTX; P4 = after 
2 doses of vaccine and CTX; P6 = after 6 vaccinations, 3 doses of CTX, 2 of IL-2) 
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Figure 2 
CTX IL-2 
Tregs identified in vaccinated patients’ PBMCs as CD4+CD25highFoxp3+ T cells were 
analyzed at different time points of the vaccination.  
 
Tregs in P1 (after one dose of CTX) showed a slight decrease if compared to those in 
P0. Their frequency regained the original level after two weeks (P4). After two doses 
of IL-2 (P6) a strong boost in Treg frequency was observed (P6 versus P0). 
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                                                       CFSE dilution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
Not proliferating cells 
Proliferating cells 
 
CD4+CD25- Tresp cells were labeled with carboxyfluorescein succinimidyl ester 
(CFSE) and their proliferation in the presence of autologous Tregs were measured 
by FACS analysis as CFSE dilution after 72h of in vitro activation with anti-
CD3/CD28 microbeads.  
 
Upon each cell division CFSEhigh cells lose half of their CFSE label resulting in 
populations of CFSElow daughter cells which can be visualized by FACS. 
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Figure 4 
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A) In all six patients analyzed IL-2 boosted both activated Tregs (Fr. b) and 
conventional T cells (Fr. a). 
 
B) Th1 markers, T-bet and IFN-γ, augmented after IL-2 administration (P6 versus P4) 
in conventional activated T cells. A fraction of Tregs displayed a Th-1 like 
phenotype, expressing ex-vivo T-bet and INF-γ, boosted after IL-2 administration.  
 
PRE IL-2 POST IL-2 
P4 P6 P4 P6 
%
 
o
f p
o
sit
iv
e 
ce
lls
 
A 
B 
Regulatory T cells in melanoma patients                                                  
 
47 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 
 
Antigen-positive T cells induced by the vaccination were evaluated as percentage of 
pentamer positive CD8+ T cells.  
 
For all the four peptides composing the vaccine, the percentage of pentamer positive 
CD8+ T cells increased after the second vaccination (P4), even if to a different 
extent, and it was further boosted after IL-2 administration (P6). 
 
PEPTIDES: 
 
a = gp100 
 
b = melanA/MART1 
 
c = NY-ESO1 
 
d = SVV-1 
                                                                                       Chiara Camisaschi 
 
48 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 
The frequency of CD8+ T cells responding to each peptide used 
in the vaccine was evaluated by IFN-γ ELISpot assay as the 
number of CD8+ T cells releasing IFN-γ after antigen stimulation 
at different time points during the vaccine course. 
The kinetic of IFN-γ releasing peptide-specific CD8+ T cells reported together with 
the percentage of CD4+CD25highFoxp3+ T cells in PBMCs of two vaccinated 
patients during the vaccine course, showed that despite the presence and the boost 
of Tregs, there was an increase in the frequency of antigen-specific CD8+ T cells in 
both patients.  
= Survivin  
= gp100 
= NY-ESO-1 
= MelanA/MART-1 
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ONGOING RESULTS 
 
Stage III patients enrolled in the study underwent surgical LNs 
dissection; patients in the vaccination arm received one CTX treatment 
and two vaccinations before surgery (see for the vaccination schedule 
page 43), while patients in the control arm received neither CTX nor 
vaccine. FACS analysis of CD4+CD25highFoxp3+ activated Tregs 
performed ex-vivo on LNs cell suspension showed that LNs of vaccinated 
patients were more homogeneous in their Treg content and displayed a 
lower Treg frequency as compared to LNs of patients not receiving any 
treatment but surgery. Of note, difference in LNs Treg number between 
vaccinated and control group was more evident when comparison was 
restricted to tumor invaded LNs (figure 1). This data may suggest that 
CTX is potentially working in counteracting the generation of tumor-
induced Tregs and thus its administration reduced the level of Tregs 
frequency in tumor-invaded LNs. 
Studies are now directed toward the definition of the immunological 
status of LNs of vaccinated as well as those of control patients. 
 
 
 
Figure 1. Tregs in LNs of vaccinated patients are reduced and more homogeneous 
if compared to that of control patients. Lymphocytes obtained from patients’ LNs 
were stained with anti-CD4, -CD25 and -Foxp3 mAbs and analyzed by FACS. 
Comparison between Treg frequency (CD25highFoxp3+ cells in CD4+ lymphocytes) in 
control patients’ LNs and vaccinated patients’ LNs is reported for all the LNs examined 
(ALL LN), for LNs not tumor invade (NED-LN) and for tumor invaded LNs (TUM 
INVADED-LN). Significant p values were calculated with Student’s t Test.  
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CONCLUSION AND FUTURE PROSPECTS 
 
Role of LAG-3 in Treg biology 
 
Since we observed that LAG-3+ Tregs are functionally different from 
LAG-3- counterpart and expanded in melanoma patients, future studies 
will be aimed at evaluating the functional role of LAG-3 molecule 
expressed on melanoma patients’ Tregs and the role of melanoma in 
increasing Treg frequency. 
 
Specific objectives of future research will be the following: 
 
1. The ability of tumor cells or of cells composing the tumor stroma 
(tumor activated fibroblast and monocytes/macrophages or DCs) to 
selectively attract this discrete subset of activated LAG-3+ Tregs or their 
capacity to selectively induce LAG-3 expression in Tregs, will be 
studied.  
 
2. To fully explore the biological features of LAG-3+ Tregs, LAG-3- and 
LAG-3+ Tregs will be sorted and subjected to microarray gene 
expression profile. Genes differentially expressed by cells and/or 
pathways activated in LAG-3+ Treg could became selectively targets for 
intervention aimed at limiting the functional activities of these cells. 
 
 
Evaluation of Treg down-modulation and their impact in melanoma 
patients treated with immunotherapy 
 
Goal of my thesis was to assess the actual impact that Tregs exert on 
tumor immunity and disease progression in order to understand whether 
Treg elimination or down/modulation by pharmacological treatments can 
be of any benefit to cancer therapies.  
 
My thesis demonstrated that low-dose CTX administered during 
vaccination reduces peripheral blood Tregs only in a minority of patients 
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and this down-modulation is transient.  Thus new efforts will be done to 
design new clinical trials that will include different CTX dose and 
administration timing potentially more effective in modulating Tregs.  
 
Moreover, we observed that Tregs are present in LNs of patients who 
underwent surgery, so we will also analyze Tregs modulation due to CTX 
administration comparing lymphocytes obtained from LNs of patients 
belonging to control arm versus vaccinated arm. Treg phenotype and 
histological localization will be also taken in account with the aim of 
defining their influence on the priming of active anti-tumor responses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                       Chiara Camisaschi 
 
52 
 
REFERENCES 
1. Agarwala SS, Kirkwood JM. Interferons in melanoma. Curr Opin Oncol. 1996 
Mar;8(2):167-74.  
2. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ Jr, Wunderlich JR, 
Merino MJ, Rosenberg SA. FOXP3 expression accurately defines the 
population of intratumoral regulatory T cells that selectively accumulate in 
metastatic melanoma lesions. Blood. 2008 Dec 15;112(13):4953-60. 
3. Ahmadzadeh M, Rosenberg SA.IL-2 administration increases CD4+ CD25(hi) 
Foxp3+ regulatory T cells in cancer patients. Blood. 2006 ;107(6):2409-14. 
4. Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC.The dynamic co-
evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev 
Immunol. 2007; 7: 231-7. 
5. Andreae, S., F. Piras, N. Burdin, F. Triebel. Maturation and activation of 
dendritic cells induced by lymphocyte activation gene-3 (CD223). J. Immunol. 
2002;168:3874-3880. 
6. Annunziato, F., R. Manetti, I. Tomasevic, M.G. Guidizi, R. Biagiotti, V. 
Gianno, P. Germano, C. Mavilia, E. Maggi, S. Romagnani. Expression and 
release of LAG-3-encoded protein by human CD4+ T cells are associated with 
IFN-gamma production. FASEB J. 1996;10:769-776. 
7. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: 
Lessons of the past decade. J Transl Med. 2008 Oct 27;6:62.  
8. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. 
High-dose recombinant interleukin 2 therapy for patients with metastatic 
melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin 
Oncol. 1999 Jul;17(7):2105-16.  
9. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of 
a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-
2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. 
J Immunother. 2005 Nov-Dec;28(6):582-92. 
10. Audia S, Nicolas A, Cathelin D, Larmonier N, Ferrand C, Foucher P, Fanton A, 
Bergoin E, Maynadie M, Arnould L, Bateman A, Lorcerie B, Solary E, 
Chauffert B, Bonnotte B. Increase of CD4+ CD25+ regulatory T cells in the 
peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial 
using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T 
lymphocytes. Clin Exp Immunol. 2007 Dec;150(3):523-30. 
11. Avice, M.N., M. Sarfati, F. Triébel, G. Delespesse, C.E. Demeure. Lymphocyte 
activation gene-3, a MHC class II ligand expressed on activated T cells, 
stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. 
J. Immunol. 1999;162:2748-2753. 
12. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T 
cells. Semin Immunol. 2004;16: 89-98. 
13. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, et 
al. Metastatic melanoma: Chemotherapy. Semin Oncol. 2002 Oct;29(5):427-
45.  
14. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et 
al. Final version of 2009 AJCC melanoma staging and classification. J Clin 
Oncol. 2009 Dec 20;27(36):6199-206.  
Regulatory T cells in melanoma patients                                                  
 
53 
 
15. Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma 
staging system: the importance of sentinel node staging and primary tumor 
mitotic rate. J Surg Oncol. 2011 Sep;104(4):379-85.  
16. Barten, R., M. Torkar, A. Haude, J. Trowsdale, M.J. Wilson. Divergent and 
convergent evolution of NK-cell receptors. Divergent and convergent evolution 
of NK-cell receptors. Trends Immunol. 2001;22:52-57. 
17. Bayry, J., F. Triebel, S.V. Kaveri, D.F. Tough. Human dendritic cells acquire a 
semimature phenotype and lymph node homing potential through interaction 
with CD4+CD25+ regulatory T cells. J. Immunol. 2007;178:4184-4193. 
18. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006 Aug 
1;108(3):804-11. 
19. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts 
MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8+ T cell 
exhaustion by multiple inhibitory receptors during chronic viral infection. Nat 
Immunol. 2009 Jan;10(1):29-37.  
20. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell 
responses against melanoma. Annu Rev Immunol. 2006;24:175-208. 
21. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, 
Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, 
Battistini L, Rötzschke O, Falk K. Expression of ectonucleotidase CD39 by 
Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune 
suppression.Blood. 2007 Aug 15;110(4):1225-32. 
22. Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, 
Koenen HJ. Foxp3+ regulatory T cells of psoriasis patients easily differentiate 
into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 
2011 Sep;131(9):1853-60. 
23. Breslow A. Thickness, cross-sectional areas and depth of invasion in the 
prognosis of cutaneous melanoma. Ann Surg. 1970 Nov;172(5):902-8.  
24. Buisson, S., F. Triebel. MHC class II engagement by its ligand LAG-3 
(CD223) leads to a distinct pattern of chemokine receptor expression by human 
dendritic cells. Vaccine. 2003;21:862-868. 
25. Byun HJ, Jung WW, Lee DS, Kim S, Kim SJ, Park CG, Chung HY, Chun T. 
Proliferation of activated CD1d-restricted NKT cells is down-modulated by 
lymphocyte activation gene-3 signaling via cell cycle arrest in S phase. Cell 
Biol Int. 2007 Mar;31(3):257-62. 
26. Casati C, Camisaschi C, Novellino L, Mazzocchi A, Triebel F, Rivoltini L, 
Parmiani G, Castelli C. Human lymphocyte activation gene-3 molecules 
expressed by activated T cells deliver costimulation signal for dendritic cell 
activation. J Immunol. 2008 Mar 15;180(6):3782-8. 
27. Casati C, Camisaschi C, Rini F, Arienti F, Rivoltini L, Triebel F, Parmiani G, 
Castelli C. Soluble human LAG-3 molecule amplifies the in vitro generation of 
type 1 tumor-specific immunity. Cancer Res. 2006 Apr 15;66(8):4450-60. 
28. Chang, C.C., S. Ferrone. Immune selective pressure and HLA class I antigen 
defects in malignant lesions. Cancer Immunol. Immunother. 2007;56:227-236. 
29. Clark WH,Jr, From L, Bernardino EA, Mihm MC. The histogenesis and 
biologic behavior of primary human malignant melanomas of the skin. Cancer 
Res. 1969 Mar;29(3):705-27.  
                                                                                       Chiara Camisaschi 
 
54 
 
30. Conti P, Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tetè S, Mastrangelo 
F, Perrella A, De Lutiis MA, Tagen M, Theoharides TC. Role of mast cells in 
tumor growth. Ann Clin Lab Sci. 2007 Autumn;37(4):315-22. 
31. Correll A, Tuettenberg A, Becker C, Jonuleit H. Increased regulatory T-cell 
frequencies in patients with advanced melanoma correlate with a generally 
impaired T-cell responsiveness and are restored after dendritic cell-based 
vaccination. Exp Dermatol. 2010 Aug;19(8):e213-21. 
32. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, 
Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc. 2006 
Apr;81(4):500-7.  
33. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan 
M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, 
Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune 
privilege and predicts reduced survival. Nat Med. 2004; 10: 942-9. 
34. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta. 
2002 Sep 19;1572(2-3):285-93. 
35. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm 
P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor 
immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 
2005 Dec;115(12):3623-33. 
36. Demeure, C.J., J. Wolfers, N. Martin-Garcia, P. Gaulard, F. Triebel. T 
lymphocytes infiltrating various tumor types express the MHC class II ligand 
lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II 
interactions in cell-cell contacts. Eur. J. Cancer. 2001;73:1709-1715. 
37. Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper 
type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med. 
2011 Jun;17(6):673-5.  
38. Dunn, G.P., A.T. Bruce, H. Ikeda, L.J. Old, R.D. Schreiber. Cancer 
immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 
2002;3:991-998. 
39. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. 
Mariani, G. Parmiani, L. Rivoltini. Identification of a new subset of myeloid 
suppressor cells in peripheral blood of melanoma patients with modulation by a 
granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. 
Clin. Oncol. 2007;25:2546-2553. 
40. French, L.E., J. Tschopp. Defective death receptor signaling as a cause of 
tumor immune escape. Semin. Cancer Biol. 2002;12:51-55. 
41. Gajewski, T.F. Failure at the effector phase: immune barriers at the level of the 
melanoma tumor microenvironment. Clin. Cancer Res. 2007;13:5256-5261. 
42. Gallucci, S., P. Matzinger. Danger signals: SOS to the immune system. Curr. 
Opin. Immunol. 2001;13:114-119. 
43. Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, Gill D, 
Marlton P, Seymour J, Khanna R. Expression of LAG-3 by tumor-infiltrating 
lymphocytes is coincident with the suppression of latent membrane antigen-
specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood. 2006 Oct 
1;108(7):2280-9. 
Regulatory T cells in melanoma patients                                                  
 
55 
 
44. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic 
review of medical treatment in melanoma: current status and future prospects. 
Oncologist. 2011;16(1):5-24. 
45. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, 
Chauffert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells 
suppress tumor immunity but are sensitive to cyclophosphamide which allows 
immunotherapy of established tumors to be curative. Eur J Immunol. 2004 
Feb;34(2):336-44. 
46. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le 
Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen 
selectively depletes CD4+CD25+ regulatory T cells and restores T and NK 
effector functions in end stage cancer patients. Cancer Immunol Immunother. 
2007 May;56(5):641-8. 
47. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, 
Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake 
CG. LAG-3 regulates CD8+ T cell accumulation and effector function in 
murine self- and tumor-tolerance systems. J Clin Invest. 2007 
Nov;117(11):3383-92. 
48. Hannier, S., M. Tournier, G. Bismuth, F. Triébel. CD3/TCR complex-
associated LAG-3 molecules inhibit CD3/TCR signaling. J. Immunol. 
1998;161:4058-4065. 
49. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. 
Improved survival with ipilimumab in patients with metastatic melanoma. N 
Engl J Med. 2010 Aug 19;363(8):711-23.  
50. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, 
Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali 
DA. Role of LAG-3 in regulatory T cells. Immunity. 2004 Oct;21(4):503-13. 
51. Huard B., M. Tournier, T. Hercend, F. Triebel, F. Faure. Lymphocyte-
activation gene 3/major histocompatibility complex class II interaction 
modulates the antigenic response of CD4+ T lymphocytes. Eur. J. Immunol. 
1994b;24:3216-3221. 
52. Huard B., P. Prigent, F. Pages, D. Bruniquel, F. Triebel. T cell major 
histocompatibility complex class II molecules down-regulate CD4+ T cell 
clone responses following LAG-3 binding. Eur. J. Immunol. 1996;26:1180-
1186. 
53. Huard B., R. Mastrangeli, P. Prigent, D. Bruniquel, S. Donini, N. El-Tayar, B. 
Maigret, M. Dréano, F. Triebel. 1997. Characterization of the major 
histocompatibility complex class II binding site on LAG-3 protein. Proc. Natl. 
Acad. Sci. USA 94:5744-5749. 
54. Huard, B., M. Tournier, F. Triebel. 1998. LAG-3 does not define a specific 
mode of killing in human. Immunol. Letters 61:109-112. 
55. Huard, B., P. Gaulard, F. Faure, T. Hercend, F. Triebel. Cellular expression and 
tissue distribution of the human LAG-3-encoded protein, an MHC class II 
ligand. Immunogenetics. 1994a;39:213-217. 
56. Huard, B., P. Prigent, D. Tournier, D. Bruniquel, F. Triebel. CD4/major 
histocompatibility complex class II interaction analyzed with CD4- and 
lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur. J. Immunol. 
1995;25:2718-2721. 
                                                                                       Chiara Camisaschi 
 
56 
 
57. Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, et al. Phase 
II study of temozolomide plus pegylated interferon-alpha-2b for metastatic 
melanoma. Cancer. 2006 Jun 1;106(11):2445-51.  
58. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, Qin FX, Gilliet 
M, Liu YJ.Two functional subsets of FOXP3+ regulatory T cells in human 
thymus and periphery. Immunity. 2008; 28: 870-80. 
59. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells 
in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 
2012 Jan;13(1):e32-42. 
60. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg 
NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ, Adema GJ. Dendritic 
cell vaccination in combination with anti-CD25 monoclonal antibody 
treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res. 
2010 Oct 15;16(20):5067-78.  
61. Jandus C, Bioley G, Speiser DE, Romero P. Selective accumulation of 
differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from 
melanoma patients compared to peripheral blood. Cancer Immunol 
Immunother. 2008 Dec;57(12):1795-805.  
62. Jandus C, Speiser D, Romero P. Recent advances and hurdles in melanoma 
immunotherapy. Pigment Cell Melanoma Res. 2009 Dec;22(6):711-23.  
63. Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their 
interrelations. J Immunol. 2003 Dec 15;171(12):6323-7.  
64. Joosten, S.A., K.E. van Meijgaarden, N.D. Savage, T. de Boer, F. Triebel, A. 
van der Wal, E. de Heer, M.R. Klein, A. Geluk, T.H. Ottenhoff. Identification 
of a human CD8+ regulatory T cell subset that mediates suppression through 
the chemokine CC chemokine ligand 4. Proc. Natl. Acad. Sci. USA. 
2007;104:8029-8034. 
65. Kawamura, K., R. Bahar, W. Natsume, S. Sakiyama, M. Tagawa. Secretion of 
interleukin-10 from murine carcinoma cells suppresses systemic antitumor 
immunity and impairs protective immunity induced against tumors. Cancer 
Gene Ther. 2002;9:109-115. 
66. Kisielow, M., J. Kisielow, G. Capoferri-Sollami, K. Karjalainen. Expression of 
lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur. J. 
Immunol. 2005;35:2081-2088. 
67. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. 
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and 
leads to lasting immune-mediated rejection of breast cancers in neu-transgenic 
mice. J Immunol. 2006 Jul 1;177(1):84-91. 
68. Koebel, C.M., W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig, L.J. Old, M.J. 
Smyth, R.D. Schreiber. Adaptive immunity maintains occult cancer in an 
equilibrium state. Nature. 2007;450:903-907.  
69. Kono, K., H. Kawaida, A. Takahashi, H. Sugai, K. Mimura, N. Miyagawa, H. 
Omata, and H. Fujii. CD4(+)CD25high regulatory T cells increase with tumor 
stage in patients with gastric and esophageal cancers. Cancer Immunol. 
Immunother. 2006;55: 1064-1071. 
70. Ladányi A, Mohos A, Somlai B, Liszkay G, Gilde K, Fejos Z, Gaudi I, Tímár 
J. FOXP3+ cell density in primary tumor has no prognostic impact in patients 
with cutaneous malignant melanoma. Pathol Oncol Res. 2010 Sep;16(3):303-9. 
Regulatory T cells in melanoma patients                                                  
 
57 
 
71. Lagouros E, Salomao D, Thorland E, Hodge DO, Vile R, Pulido JS. Infiltrative 
T regulatory cells in enucleated uveal melanomas. Trans Am Ophthalmol Soc. 
2009 Dec;107:223-8. 
72. Lee SM, Betticher DC, Thatcher N. Melanoma: Chemotherapy. Br Med Bull. 
1995 Jul;51(3):609-30.  
73. Lehmann, C., M. Zeis, N. Schmitz, L. Uharek. Impaired binding of perforin on 
the surface of tumor cells is a cause of target cell resistance against cytotoxic 
effector cells. Blood. 2000;96:594-600. 
74. Li, N., Y. Wang, K. Forbes, K. M. Vignali, B. S. Heale, P. Saftig, D. 
Hartmann, R. A. Black, J. J. Rossi, C. P. Blobel, P. J. Dempsey, C. J. 
Workman, D. A. Vignali. 2007. Metalloproteases regulate T-cell proliferation 
and effector function via LAG-3. EMBO J. 26:494-504. 
75. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. 
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced 
immune response by low-dose cyclophosphamide. Blood. 2005 Apr 
1;105(7):2862-8. 
76. Machy, P., K. Serre, M. Baillet, L. Leserman. Induction of MHC class I 
presentation of exogenous antigen by dendritic cells is controlled by CD4+ T 
cells engaging class II molecules in cholesterol-rich domains. J. Immunol. 
2002;168:1172-1180. 
77. Madhavan, M., P. Srinivas, E. Abraham, I. Ahmed, N.R. Vijayalekshmi, P. 
Balaram. Down regulation of endothelial adhesion molecules in node positive 
breast cancer: possible failure of host defence mechanism. Pathol. Oncol. Res. 
2002;8:125-128. 
78. Maeurer, M.J., S.M. Golin, D. Martin, W. Swaney, J. Bryant, C. Castelli, P. 
Robbins, G. Parmiani, W.J. Storkus, M.T. Lotze. Tumor escape from immune 
recognition: lethal recurrent melanoma in a patient associated with 
downregulation of the peptide transporter protein TAP-1 and loss of expression 
of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 
1996;98:1633-1641. 
79. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-
promoting tumor-associated macrophages: new vistas and open questions. Eur 
J Immunol. 2011 Sep;41(9):2522-5. doi: 10.1002/eji.201141894. Review 
80. Mastrangeli, R., E. Micangeli, S. Donini. Cloning of murine LAG-3 by 
magnetic bead bound homologous probes and PCR (gene-capture PCR). Anal. 
Biochem. 1996;241:93-102. 
81. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, 
Eppolito C, Qian F, Lele S, Shrikant P, Old LJ, Odunsi K. Tumor-infiltrating 
NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 
in human ovarian cancer. Proc Natl Acad Sci U S A. 2010 Apr 
27;107(17):7875-80. 
82. McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W, 
Wilson C, Palmer BE, Gonzalez R. Immunosuppressive dendritic and 
regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007 
Oct;14(10):2854-60. 
83. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. 
Randomized phase III study of temozolomide versus dacarbazine in the 
treatment of patients with advanced metastatic malignant melanoma. J Clin 
Oncol. 2000 Jan;18(1):158-66.  
                                                                                       Chiara Camisaschi 
 
58 
 
84. Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti I, 
Cosci E, Tosi P, Luzi P. Utility of tumor-infiltrating CD25+FOXP3+ 
regulatory T cell evaluation in predicting local recurrence in vertical growth 
phase cutaneous melanoma. Oncol Rep. 2007 Nov;18(5):1115-22. 
85. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin 
C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono 
M, Amoura Z, Gorochov G, Sakaguchi S. Functional delineation and 
differentiation dynamics of human CD4+ T cells expressing the FoxP3 
transcription factor. Immunity. 2009 Jun 19;30(6):899-911. 
86. Miyazaki, T., A. Dierich, C. Benoist, D. Mathis. Independent modes of natural 
killing distinguished in mice lacking LAG-3. Science. 1996a;272:405-408. 
87. Mougiakakos D, Choudhury A, Lladser A, Kiessling R, Johansson CC. 
Regulatory T cells in cancer. Adv Cancer Res. 2010;107:57-117.  
88. Mourmouras V, Fimiani M, Rubegni P, Epistolato MC, Malagnino V, Cardone 
C, Cosci E, Nisi MC, Miracco C. Evaluation of tumour-infiltrating 
CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and 
atypical naevi, melanomas and melanoma metastases. Br J Dermatol. 2007 
Sep;157(3):531-9.  
89. Nakano Y, Kuroda E, Kito T, Yokota A, Yamashita U. Induction of 
macrophagic prostaglandin E2 synthesis by glioma cells. J Neurosurg. 2006 
Apr;104(4):574-82. 
90. Nizar S, Meyer B, Galustian C, Kumar D, Dalgleish A. T regulatory cells, the 
evolution of targeted immunotherapy. Biochim Biophys Acta. 2010 
Aug;1806(1):7-17.  
91. Novellino L, Castelli C, Parmiani G. A list of human tumor antigens 
recognized by T cells: March 2004 update. Cancer Immunol Immunother. 2005 
Mar;54(3):187-207.  
92. Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, Kato Y, 
Fagarasan S, Muramatsu M, Eto T, Hioki K, Honjo T. PD-1 and LAG-3 
inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J 
Exp Med. 2011 Feb 14;208(2):395-407.  
93. Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory T cells in 
cancer patients. Hum Immunol. 2008; 69: 241-9. 
94. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse 
signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007 
Oct;7(10):817-23.  
95. Raffin C, Raimbaud I, Valmori D, Ayyoub M. Ex vivo IL-1 receptor type I 
expression in human CD4(+) T cells identifies an early intermediate in the 
differentiation of Th17 from FOXP3(+) naive regulatory T cells. J Immunol. 
2011 Nov 15;187(10):5196-202. 
96. Rivoltini, L., P. Canese, V. Huber, M. Iero, L. Pilla, R. Valenti, S. Fais, F. 
Lozupone, C. Casati, C. Castelli, G. Parmiani. Escape strategies and reasons for 
failure in the interaction between tumour cells and the immune system: how 
can we tilt the balance towards immune-mediated cancer control? Expert Opin. 
Biol. Ther. 2005;5:463-476. 
97. Roncarolo MG, Levings MK. The role of different subsets of T regulatory cells 
in controlling autoimmunity. Curr Opin Immunol. 2000 Dec;12(6):676-83.  
98. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and 
immune tolerance. Cell. 2008 May 30;133(5):775-87.  
Regulatory T cells in melanoma patients                                                  
 
59 
 
99. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-
tolerance and negative control of immune responses. Annu Rev Immunol. 
2004;22:531-62.  
100. Schmielau, J., O.J. Finn. Activated granulocytes and granulocyte-derived 
hydrogen peroxide are the underlying mechanisms of suppression of T-cell 
function in advanced cancer patients. Cancer Res. 2001;61:4756-4760. 
101. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, 
Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, 
Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, 
Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke 
P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with 
advanced melanoma. N Engl J Med. 2011 Jun 2;364(22):2119-27. 
102. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, 
Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St 
Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates 
between human regulatory and activated T cells. J Exp Med. 2006 Jul 
10;203(7):1693-700.  
103. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. 
Immunomodulatory effects of cyclophosphamide and implementations for 
vaccine design. Semin Immunopathol. 2011 Jul;33(4):369-83. 
104. Smith LM, Osborne RF. The karapandzic flap in recurrent melanoma of the lip. 
Ear Nose Throat J. 2004 Oct;83(10):684, 698.  
105. Solstad T, Bains SJ, Landskron J, Aandahl EM, Thiede B, Taskén K, Torgersen 
KM. CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-
activated human regulatory T cells. Blood. 2011 Nov 10;118(19):5141-51. 
106. Speeckaert R, van Geel N, Vermaelen KV, Lambert J, Van Gele M, Speeckaert 
MM, Brochez L. Immune reactions in benign and malignant melanocytic 
lesions: lessons for immunotherapy. Pigment Cell Melanoma Res. 2011 
Apr;24(2):334-44.  
107. Staveley-O'Carroll, K., T.D. Schell, M. Jimenez, L.M. Mylin, M.J. Tevethia, 
S.P. Schoenberger, S.S. Tevethia. In vivo ligation of CD40 enhances priming 
against the endogenous tumor antigen and promotes CD8+ T cell effector 
function in SV40 T antigen transgenic mice. J. Immunol. 2003;171:697-707. 
108. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, 
master of regulation. Nat Immunol. 2008 Mar;9(3):239-44.  
109. Teicher, B.A. Transforming growth factor-beta and the immune response to 
malignant disease. Clin. Cancer Res. 2007;13:6247-6251. 
110. Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, Old LJ, Valmori 
D, Ayyoub M. Differential expression of CCR7 defines two distinct subsets of 
human memory CD4+CD25+ Tregs. Clin Immunol. 2008 Mar;126(3):291-302.  
111. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP 
(LRRC32) is essential for the surface expression of latent TGF-beta on 
platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 
2009 Aug 11;106(32):13445-50. 
112. Triebel F, Hacene K, Pichon MF. A soluble lymphocyte activation gene-3 
(sLAG-3) protein as a prognostic factor in human breast cancer expressing 
estrogen or progesterone receptors. Cancer Lett. 2006 Apr 8;235(1):147-53. 
113. Triébel, F. LAG-3: a regulator of T-cell and DC responses and its use in 
therapeutic vaccination. Trends Immunol. 2003;24:619-622. 
                                                                                       Chiara Camisaschi 
 
60 
 
114. Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-
Pequignot E, Hercend T. LAG-3, a novel lymphocyte activation gene closely 
related to CD4. J Exp Med. 1990 May 1;171(5):1393-405. 
115. Viguier M, Lemaître F, Verola O, Cho MS, Gorochov G, Dubertret L, 
Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4+CD25(high) 
regulatory T cells are overrepresented in human metastatic melanoma lymph 
nodes and inhibit the function of infiltrating T cells. J Immunol. 2004 Jul 
15;173(2):1444-53. 
116. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, 
Kaiser LR, June CH. Regulatory CD4(+)CD25(+) T cells in tumors from 
patients with early-stage non-small cell lung cancer and late-stage ovarian 
cancer. Cancer Res. 2001 Jun 15;61(12):4766-72. 
117. Woo SR, Li N, Bruno TC, Forbes K, Brown S, Workman C, Drake CG, 
Vignali DA. Differential subcellular localization of the regulatory T-cell 
protein LAG-3 and the coreceptor CD4. Eur J Immunol. 2010 Jun;40(6):1768-
77. 
118. Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA. Phenotypic 
analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J 
Immunol. 2002 Aug;32(8):2255-63. 
119. Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, 
Vignali DA. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J 
Immunol. 2009 Feb 15;182(4):1885-91. 
120. Workman, C.J., K.J. Dugger, D.A.A. Vignali. Cutting edge: molecular analysis 
of the negative regulatory function of lymphocyte activation gene-3. J. 
Immunol. 2002b;169:5392-5395. 
121. Zhang, X.M., Q. Xu. Metastatic melanoma cells escape from 
immunosurveillance through the novel mechanism of releasing nitric oxide to 
induce dysfunction of immunocytes. Melanoma Res. 2001;11:559-567. 
122. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY. 
Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory 
T-cell fate. Nature. 2010 Feb 11;463(7282):808-12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory T cells in melanoma patients                                                  
 
61 
 
ACKNOWLEDGEMENTS 
 
I would like to express my sincere gratitude to my supervisor Dr. Chiara 
Castelli; this thesis would not have been possible without her invaluable 
help and wise advises.   
I would also like to thank everyone who supported me during these years 
of work, my fantastic colleagues and my family in particular. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                       Chiara Camisaschi 
 
62 
 
                                                               PART II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory T cells in melanoma patients                                                  
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64
65
66
67
68
69
70
71
                                                                                       Chiara Camisaschi 
 
72 
 
Manuscript 
 
Title: “Frequency and function of circulating regulatory T cells in 
melanoma patients receiving peptide-based vaccine” 
 
Authors: 1,§Camisaschi Chiara, 1,§Filipazzi Paola, 1,§Casati Chiara, 
1,§Beretta Valeria, 2,3Maio Michele, 4Chiarion-Sileni Vanna, 5Tragni 
Gabrina, 6Santimani Mario, 7Parmiani Giorgio, 1,§Rivoltini Licia and 
1,§Castelli Chiara. 
1Unit of Immunotherapy of Human Tumors; 2Division of Medical 
Oncology and Immunotherapy, Department of Oncology, University 
Hospital of Siena, Istituto Toscano Tumori, 53100 Siena, Italy; 3Cancer 
Bioimmunotherapy Unit, Department of Medical Oncology, Centro di 
Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere 
Scientifico, Aviano, Italy; 4Medical Oncology Unit, Istituto Oncologico 
Veneto-IRCCS, 6435128 Padova, Italy; 5Department of Pathology; 
6Melanoma and Sarcoma Unit; 7Immunobiotherapy of Melanoma and 
Solid Tumors Unit, San Raffaele Scientific Institute, 20132 Milan, Italy; 
§Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy. 
 
Running title: Melanoma vaccine and Treg modulation 
 
Keywords: Regulatory T cells, melanoma, vaccination, IL-2, 
Cyclophosphamide 
 
Research article: Clinical Cancer Therapy  
 
 
 
 
Regulatory T cells in melanoma patients                                                  
73 
 
ABSTRACT  
 
Purpose: Regulatory T cells (Tregs) exert a detrimental effect on tumor 
immunity.  We evaluated the influence of low-dose cyclophosphamide 
(CTX), low-dose interleukin-2 (IL-2) and peptide vaccination on the 
frequency and functional behavior of Tregs of melanoma patients. Impact 
of Tregs on antigen-specific response was also investigated. 
 
Experimental Design: Tregs were analyzed by multiparametric 
fluorescence-activated cell sorting (FACS) in peripheral blood 
mononuclear cells (PBMCs) of melanoma patients vaccinated with HLA-
A*0201 tumor peptides and compared to Tregs in control patients not 
receiving any treatment but surgery. Vaccinated patients received CTX 
(300 mg/m2 i.v.) before the first, the third and the fifth vaccination and 
two injections of low dose IL-2 (3x106 IU).  
 
Results: Frequency of Tregs dropped in PBMCs collected 4-7 days after 
CTX administration, with 6 out of 13 patients displaying a reduction 
ranging from 20 to 65 %.  Tregs regained the original pre-treatment level 
in few weeks. Low dose IL-2 expanded both circulating conventional 
activated CD4+ T cells and Tregs; a fraction of these Tregs displayed a 
Th-1 like phenotype, expressing ex-vivo T-bet and INF-γ.  No Treg 
modulation was detectable in control patients.  Ex-vivo HLA-
A*0201/peptide multimer (HLA-multimer) staining and  IFN-γ  ELISpot 
assays indicated that peptide-specific T cells induced  in vaccinated 
patients were further boosted following IL-2 administration.  
 
Conclusions: Low dose CTX has a limited efficacy and its effect is 
transient. In a vaccination setting, Tregs boosted by low dose IL-2 do not 
limit the vaccine induced immune-responses. CD4+ cells boosted by IL-2 
include conventional activated T cells, suppressive Tregs and Tregs that 
in the pro-inflammatory environment created by the vaccine display 
functional plasticity acquiring a Th-1 like phenotype.  
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TRANSLATIONAL RELEVANCE  
 
Drugs depleting Tregs may favor the efficacy of immune-based therapy 
of cancer.  Conversely IL-2 mediated boosting of Tregs may limit the 
expansion of tumor-specific T cells.  Our data indicate that CTX reduces 
Tregs only in a minority of the patients and this down-modulation is 
transient, thus underscoring the need to further explore a more effective 
schedule of CTX administration. CD4+ T cells boosted by low dose IL-2 
include conventional activated T cells, suppressive Tregs and Tregs 
acquiring a Th-1 like phenotype likely induced by the pro-inflammatory 
environment created by the vaccine. Our study provides definitive 
evidence that low dose of IL-2 given in a vaccination setting, although 
expanding Tregs, does not produce detrimental effect on the expansion 
and functional activities of antigen-specific CD8+ T cells induced by 
vaccination. The balance among the different functional T cell subsets 
amplified by IL-2 is most likely influencing the immunological and 
clinical outcome of the vaccinated patients. 
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INTRODUCTION   
 
Tregs are essential for the maintenance of self tolerance and immune 
homeostasis; their archetypal feature is the ability to suppress, mostly in a 
contact-dependent fashion, the activation, proliferation and effector 
functions of a wide variety of immune cells (1). 
The relevance of CD4+ Tregs in suppressing anti-tumor immune 
response is well accepted for murine tumors (2). In humans, several 
studies reported an increase in circulating CD4+ Tregs in patients with 
various types of cancers and accumulation of Tregs is generally 
associated to tumor progression and bad prognosis (3-5). The influence of 
Tregs in down-modulating anti-tumor immunity in cancer patients is 
under intense investigation and several strategies have been employed to 
block or to eliminate Tregs (6-8). With the aim of reducing Treg number, 
cyclophosphamide (N,N-bis (2-chloroethyl)-1, 3, 2- oxazaphosphinan-2 
amine 2-oxide, the generic name for Cytoxan (CTX), Endoxan) is used to 
treat a variety of diseases: solid and hematological malignancies, 
autoimmune disorder and transplantations. CTX limits the number of 
circulating Tregs in murine models (9, 10).  The biological activities of 
CTX are dose dependent and metronomic dosing has been shown to 
possess strong capacity in limiting Treg expansion in advanced cancer 
patients (11, 12).  However, when administered at low dose, biological 
effects of CTX are less clear and conflicting results have been reported 
probably due to the different schedule of administration as well as to the 
different methods used to detect Tregs (13-15).  
In humans, Tregs represent less than 10% of the whole CD4+ T cells. 
They constitutively express IL-2 receptor α-chain (CD25) and Foxp3, 
together with low level of CD127 (16, 17). Naturally occurring Tregs, 
ready to exert their suppressive activities, namely activated Tregs, are 
defined as CD4+CD25hiFoxp3+ T cells (18).  
The discovery of a CpG dinucleotides sequency in the first intron of 
FOXP3 gene specifically demethylated in Tregs and detected by a 
methylation-specific qPCR assay has been recently proposed as a more 
precise method to detect population of human Tregs (19, 20). However, 
this method of Treg definition cannot be used for a direct quantification 
of Tregs inside tumor samples (21) and, most importantly, it cannot be 
associated to any ex-vivo functional studies. Conversely, the 
multiparametric Treg definition using anti -CD4, -CD25 and anti-Foxp3 
mAbs allows the combination of additional markers aimed at defining ex-
vivo the functional properties of the identified T cell subsets. This 
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implementation is crucial in view of the functional heterogeneity and 
high lineage plasticity of Tregs (1, 22-24).   
In this study, taking advantage of a phase II randomized trial of stage IIB-
C/III HLA-A*0201 melanoma patients (peptide vaccination versus 
observation), we assessed the in vivo effect of CTX and IL-2 on Treg 
modulation. Tregs was investigated combining phenotypic and functional 
markers aimed at dissecting their plasticity in the context of vaccination.  
Extensive immunological monitoring of the vaccine–induced T cell 
responses was performed to understand whether the modulation of the 
frequency and functional behavior of Tregs impacted patients’ immune-
response to the vaccine. 
 
 
MATERIALS AND METHODS   
Study design and patients’ eligibility criteria 
This was a phase II randomized study involving HLA-A*0201 patients 
with melanoma (stage IIB/C-III). The study included a vaccination and 
an observation arm.  
The peptides used in the present study were synthesized under GMP 
conditions by Merck Biosciences AG Clinalfa (>95% purity). The 
vaccine included four altered peptide ligands (APLs): HLA-A*0201-
restricted (Melan-A/MART-1[27L], gp100[210M], NY-ESO-1[165V], 
and Survivin[97M]); 250 µg of each peptide was emulsified in 
Montanide-ISA51 (0.5 ml, Seppic, Franklin Lakes, NJ) and injected 
subcutaneously (s.c.) close to the inguinal/axillary LN in combination 
with CTX (ENDOXAN) (300 mg/m2) and IL-2 (PROLEUKIN) (3x106 
IU). Schedule is detailed in Figure 1S. 
Patients were selected after primary tumor removal and were enrolled at 
the Istituto Nazionale Tumori of Milan (N=37), Azienda Ospedaliera 
Universitaria Senese (N=4), and Istituto Oncologico Veneto of Padova 
(N=2). The protocol was conducted in compliance with the Declaration 
of Helsinki and was approved by the ethical committees of each 
institution. Written informed consent was obtained. Patients with 
histologically confirmed (American Joint Committee on Cancer) stage 
IIB/C-III resectable melanoma (ECOG score 0–1) and normal 
hematopoietic, liver and renal function were eligible. Patients were 
checked for HLA-A*0201 expression using an OLERUP SSPTM HLA 
kit (Qiagen S.p.A, Milan, Italy). Of the 43 patients enrolled, 22 were 
randomized into vaccination arm and 21 into observation arm (receiving 
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neither vaccination nor IL-2 and cyclophosphamide). Two patients 
belonging to the vaccination arm did not complete the treatment. 
 
Blood and tissue samples 
Upon written informed consent, blood samples were collected from 
healthy donors and patients. PBMCs were isolated by Ficoll/PaqueTM 
PLUS density gradient centrifugation as previously described (25). 
Donors’ and patients’ sera was obtained from blood cells by high speed 
centrifugations and stored at -30˚ C.  
 
Treg analysis 
Thawed PBMCs were analyzed by FACS after staining with the 
following mAbs: APCH7 or APC-conjugated anti-CD4, PE-Cy7-
conjugated anti-CD25, FITC-conjugated anti-CD45RA and, as an isotype 
control, fluorochrome-conjugated mouse IgG (all from BD Biosciences, 
San Josè, CA); PE- or APC-conjugated anti-Foxp3 as intracellular 
staining using eBioscience buffers according to manufaturer’s protocol 
(eBioscience, San Diego, CA).  
Intracellular staining was performed as follows: lymphocytes freshly 
isolated or activated overnight with anti-CD3/CD28 beads (DynaBeads® 
CD3/CD28 T cell Expander, Invitrogen Dynal AS, Oslo, Norway) in the 
presence of 1 µl/ml Golgi Plug (BD Biosciences), were stained for cell 
surface markers CD4 and CD25, washed, fixed and permeabilized with 
Cytofix/Cytoperm buffer (BD Biosciences) and then stained with PE-
labeled anti-IFNγ or  FITC-labeled anti-Ki67 (all from BD Biosciences), 
PE-labeled anti-T-bet (eBioscience) or PE-labeled anti-TGF-β1 (IQ 
Products, Groningen, The Netherlands). If combined with anti-Foxp3, 
staining was performed using eBioscience Fixation/Permeabilization 
buffers. The fluorescence intensity was evaluated using a BD 
FACSCalibur® or NaviosTM (Beckman Coulter, Brea, CA) flow 
cytometer and analyzed using FlowJo® Cytometry Analysis software 
(Tree Star Inc, Ashland, OR). 
 
Isolation of CD4+CD25+ T cells  
CD4+CD25+ T cells were purified from freshly isolated PBMCs by 
immunomagnetic sorting using human CD4+CD25+ Regulatory T Cell 
Isolation Kit following the manufacturer’s instructions (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Purity of the isolated cells (> 95%) was 
checked by surface staining with anti-CD4 and anti-CD25 mAbs.  
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Suppression assay 
In vitro suppression assays were performed in 96-well round-bottom 
plates and evaluated by Carboxyfluorescein Succinimidyl ester (CFSE) 
proliferation assay as previously described (26). The proliferation of the 
responder T cells was evaluated after 72 hours and the percentage of 
proliferation’s inhibition calculated as follows:  
% of inhibition = 100 x [1- (mean proliferation (responder and 
suppressor) / mean proliferation (responder only with beads)] 
 
Cytokines flow cytomix 
Sera IL-12p70 levels and IFNγ release in SN of anti-CD3/CD28 beads 
activated PBMCs were measured by FlowCytomixTM multiple analyte 
detection kit (eBioscience) according to the manufacturer’s protocol. 
Cytokines production was evaluated as fluorescence intensity with a BD 
FACSCalibur® flow cytomiter and quantified by the Pro 2.4 
FlowCytomixTM software. 
 
ELISpot 
Immunomonitoring was performed by ex-vivo IFNγ-Enzyme-Linked 
Immunospot (ELISpot) assay (1-D1K, MabTech AB, Nacka, Sweden) 
after incubating thawed PBMCs overnight at 37°C in culture medium, as 
previously described (27). Data were evaluated by a computer-assisted 
ELISpot reader A.EL.VIS. (Thema Ricerca, Bologna, IT). Results are 
presented as the number of APL-reactive cells/2×105 CD8+ cells.  
 
Multimer staining 
HLA-A*0201-multimers, including the irrelevant HLA-A*0201/HIV-p24 
peptide (HIVgag24; TLNAWVKVV), were provided by Proimmune 
(Ltd, Oxford, UK) and used as previously described (25). Fluorescence 
intensity was evaluated using a BD FACSCalibur® flow cytometer and 
analyzed using FlowJo® Cytometry Analysis software (Tree Star Inc, 
Ashland, OR). A phycoerythrin-conjugated HLA-A*0201-negative 
multimer was used as a control. 
 
Statistics 
Student’s t Test and two-tailed Wilcoxon’s matched pairs test 
(Confidence Interval [Cl] 95%) were used as indicated in graph’s 
legends. Statistical calculations were carried out using Prism5 software 
(GraphPad Software, La Jolla, CA, USA). p-values ≤0.05 were 
considered statistically significant. 
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RESULTS AND DISCUSSION     
 
Modulation of Tregs in melanoma vaccinated patients 
 
HLA-A*0201 stage IIB/C-III melanoma patients were enrolled in the 
study and they underwent vaccination or observation. As potential Treg-
depleting agent, patients in the vaccination arm received  low-dose CTX 
(300 mg/m2 i.v.) 1 week before and 7 and 11 weeks after the initiation of 
vaccination. To boost vaccine-induced immune-responses, they also 
received at week 13 and 15 three daily injections of low dose IL-2 (3x106 
IU). In the control arm, patients received no treatment beside surgery 
(observation only) (Supplementary Figure 1S).  
Melanoma patients enrolled in the study displayed a baseline frequency 
of circulating Tregs slightly enriched as compared to that of age and sex 
matched healthy donors either if Tregs were identified as 
CD4+CD25hiFoxp3+ activated Tregs or broadly defined as T cells 
positive for CD4+CD25+Foxp3+ (Supplementary Figure 2S).  
Blood samples were serially collected at different time points 
(Supplementary Figure 1S) from patients enrolled in the vaccination 
(n=16) and observation (n=19) arms and frequency of Tregs monitored 
by FACS analysis. As compared to pre-treatment, frequency of 
CD4+CD25hiFoxp3+ Tregs dropped in PBMCs collected 4-7 days after 
CTX administration (P1 versus P0, Figure 1A). Six out of 13 patients for 
whom paired pre-post CTX blood samples were available displayed a 
reduction of Tregs frequency ranging from 20 to 65 % (P1 versus P0, 
Figure 1B). Of note at this stage patients only received CTX, since 
vaccination started after week 1. However, this reduction was transient 
and although patients received additional CTX, the frequency of Tregs at 
week 8 (P4, Figure 1A) regained the original pre-treatment level.  
Low dose IL-2 induced a significant expansion of the CD4+ T cells 
compartment (P6, Supplementary Figure 3S) and strongly boosted the 
number of circulating CD4+CD25hiFoxp3+ Tregs (P6, Figure 1A). Two 
to 9 fold increase in the percentage of CD4+CD25hiFoxp3+ Tregs was 
detected in those patients receiving IL-2 for whom blood sample at day 7 
after IL-2 administration was available (P6 versus P4, Figure 1C).  Three 
patients, namely Pt # 9, 11 and 28 received only the first cycle of IL-2 
and PBMCs collected at week 16, 22 days after the first IL-2 
administration, displayed a lower increase in Tregs frequency (Figure 1C) 
suggesting the transient nature of the IL-2 induced  Treg boosting.  Treg 
frequency profile for Pt # 1, for whom PBMCs collected at additional 
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time points during the vaccination course were available for analysis, 
confirmed that CD4+CD25hiFoxp3+ Treg boost occurring at day 7 after 
IL-2 administration is transitory and no longer detectable after 15 days 
(Supplementary Figure 4S). No significant variation in Tregs was 
detectable in the cohort of patients enrolled in the control arm (Figure 
1D, E, F). Frequency of CD4+CD25+Foxp3+ T cells displayed a similar 
modulated profile as that of CD4+CD25hiFoxp3+ activated Tregs in 
vaccinated and control patients (Supplemental Figure 5S A, B).  
In Tregs, stable FOXP3 expression is ensured by a selective 
demethylation of a conserved region in the FOXP3 intron 1. This specific 
demethylation is unique for Tregs, thus, an alternative method to detect 
Tregs relies on methylation specific quantitative PCR assays (MS-qPCR). 
MS-qPCR assay, performed on a set of patients’ PBMCs, confirmed the 
CTX and IL-2 mediated effect on Tregs. Down-modulation of Tregs 
frequency was detected in 5 out of 6 patients for whom DNA of PBMCs 
in P0 (day -7) and P1 (day 0), pre-post CTX, was available. Boost of 
Tregs in P6 (day 112) induced by IL-2 was found in all the patients 
analyzed by MS-qPCR (n=9) (28).   
 
  
Circulating Tregs exerted suppressive activity 
 
TGF-β is a key cytokine mediating Treg suppressive functions (29, 30). It 
regulates many aspects of immunological networks and it directly impairs 
both NK and T cell functions (31, 32). Moreover, variation in the 
frequency of TGF-β producing Tregs may impact clinical outcome as 
shown in a phase II dendritic-based vaccination trial in which vaccine-
induced reduction of circulating TGF-β+ Tregs in patients’ PBMCs  was 
associated to a prolong survival and disease stability (33).  
In our study, we evaluated the functional status of circulating 
CD4+CD25hiFoxp3+ Tregs by analyzing ex-vivo their capacity to 
produce TGF-β1 upon TCR stimulation. As reported in figure 2A, few 
TGF-β1+ CD25hi T cells were detectable in the CD4+ T cell compartment 
at the baseline both in vaccinated and in control patients and thus no 
significant decrease could be evidenced after CTX treatments. For three 
patients, namely Pt # 8, 9 and 28, displaying at baseline a higher number 
of TGF-β1+ Tregs, a slight reduction was detected in PBMCs collected 4 
days after CTX (Supplementary Figure 6S). Conversely, a significant 
increase in the frequency of TGF-β1 producing Tregs was detected in 
PBMCs of vaccinated patients after IL-2 administration (P6, Figure 2A). 
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No down-modulation was observed in PBMCs of patients enrolled in the 
observation arm (Figure 2B and Supplementary Figure 6S). 
We assessed whether Tregs  found in PBMCs after IL-2 administration 
were endowed with the capacity to inhibit the proliferation of 
conventional CD4+CD25- T cells; for Pt # 4 sufficient material was 
available to sort CD4+CD25hi Tregs from PBMCs pre-vaccine (P0, week 
-1) and post IL-2 treatment (P6, week 11) to assess their suppressive 
capacity in vitro. In vitro suppression assays were set up using as 
responder CD4+CD25- T cells isolated form autologous pre-vaccine 
PBMCs. Data reported in Figure 3 clearly show that Tregs isolated after 
IL-2 administration displayed contact-dependent inhibitory activity 
further supporting the notion that IL-2 indeed boost a population of 
functional Tregs.  
Collectively these data are in line with previous reports showing that high 
dose of IL-2 expands T cells with regulatory phenotype in vivo (34). Here 
we extend this notion by showing that also low dose IL-2, as those 
administrated in our clinical study during an on-going peptide 
vaccination, directly affects Treg homeostasis by inducing an expansion 
of suppressive-competent Tregs. 
 
 
Conventional CD4+T cells were also boosted in vivo by IL-2 
 
In cancer patients, increase frequency of circulating Tregs and their 
accumulation at tumor site is associated with unfavorable prognosis and 
limited overall survival (4, 35). Tumor-specific Tregs actively suppress 
the proliferation of CD4+CD25- and CD8+ effector T cells, thereby 
limiting the immune response against cancer and contributing to tumor 
growth (36, 37). These immune suppressive functions and the ability of 
IL-2 to boost in vivo Tregs may provide indication for discontinuing the 
in vivo usage of this cytokine in therapeutic vaccination of cancer 
patients.  Conversely, several independent clinical trials have consistently 
shown that administration of IL-2 into immune competent patients results 
in 15% to 20% objective clinical responses with 7% complete long-term 
responders (38, 39). Few explanations may account for the finding that, 
although increasing Tregs, IL-2 is nevertheless inducing a positive 
clinical outcome. One of the mechanisms may include a better homing of 
T lymphocytes at tumor site.  
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In our study we investigated the hypothesis that, in addition to boost 
Tregs, IL-2 favors the expansion of conventional CD4+ T cells 
potentially including Th1 anti-tumor T cells. 
Thus to assess whether IL-2 was indeed able to modulate conventional 
activated CD4+ T cells, PBMCs pre and post IL-2 of 6 vaccinated 
patients were stained with CD4, Foxp3, CD25 and CD45RA markers. 
The addition of CD45 marker allows to phenotypically define 
conventional activated CD4+ T cells that have intermediate levels of 
CD25 molecules and transiently express Foxp3 (40,41), but are negative 
for CD45 (Figure 4A, Fr. a: CD4+CD25intFoxp3intCD45RAneg) (18). 
CD4+CD25hiFoxp3+ activated Tregs are gated in Fr.b (Figure 4A). With 
this gating strategy, the analysis performed for 6 vaccinated patients and 
reported in figure 4B confirms that IL-2 indeed boosted Tregs and it also 
shows that, in all the 6 analyzed patients, IL-2 led to a variable although 
consistent enhancement of conventional activated CD4+ T cells.  
Activated T cells and Tregs in PBMCs pre and post IL-2 of 3 
representative patients were characterized ex-vivo for their proliferation 
capacity evaluated as positivity for Ki67, a nuclear protein expressed by 
proliferating cells in all phases of the active cell cycle (42) and for the 
expression of T-bet, a Tbox transcription factor crucial for effector Th1 
CD4+ T cells commitment and so far the most specific marker for this T-
cell subset (43) (Figure 4C-D).  Activated conventional CD4+ T cells 
included T-bet positive cells, whose percentage increased in PBMCs post 
IL-2 (Figure 4C). Since the T-box transcription factor T-bet controls the 
expression of IFN-γ, the hallmark of Th1 cytokine (44), CD4+ T cells in 
PBMCs of vaccinated patients were evaluated  for their capacity to 
produce  ex-vivo this Th1 cytokine upon TCR triggering. In activated 
conventional cells increase in T-bet positive cells paralleled the increase 
in the percentage of T cells producing IFN-γ  (Figure 4C). Thus these 
data support the conclusion that, in addition to functionally suppressive 
Tregs, IL-2 may also expand activated CD4+ T cells producing Th1 
related cytokines. 
 
 
Functional plasticity of Tregs in vaccinated patients 
 
Surprising  enough,  after IL-2 treatment expression of T-bet was present 
and boosted also in the fraction of cells containing activated Tregs 
(Figure 4D) and the percentage of Tregs functionally competent in IFN-γ 
production was  strongly increased in PBMCs post IL-2 (Figure 4D and 
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4E). No variation occurred in PBMCs of patients in the control arm 
(Figure 4F).  
Tregs found in PBMCs post IL-2, at the end of the vaccination cycle, 
displayed a phenotype similar to the recently described T helper type 1-
like Foxp3+ regulatory T cells. Indeed, natural Tregs are endowed with 
extensive functional plasticity and their conversion in Th-1 like Tregs 
producing INF-γ has been recently described in the context of 
autoimmune diseases and in a vaccination setting (45-47).  IL-12 was 
shown to be the key cytokine inducing such a phenotypic shift (45).  
Monitoring of IL-12p70 confirmed that, also in our vaccinated patients, 
an increase in the levels of this cytokine was detectable in sera collected 
post vaccine as compared to pre-treatment sera,  to sera of patients 
enrolled in the control arm or to sera of healthy donors (Supplementary 
Figure 7S). These data support the hypothesis that, in a vaccination 
setting, favoring a pro-inflammatory environment characterized by 
enhanced level of IL-12, Tregs may undergo to functional plasticity and 
acquire Th-1 like phenotype. These functionally modulated Tregs can be 
then expanded in number by the local availability of IL-2. 
 
 
IL-2 induced Treg boosting was not hampering the vaccine induced 
immunity 
 
Extensive analysis was performed assessing the immunological status of  
patients enrolled in the study either in the vaccine or in the control arm; 
monitoring of peptide specific, vaccine-induced T cells was performed  
ex-vivo by HLA-A*0201/peptide multimer (HLA-multimer) staining and 
by  IFN-γ  ELISpot assays at different time points during vaccination.  
As reported in Figure 5A, the percentage of tetramer positive cells, 
increased after the 2nd vaccination, was further boosted at week 16, at the 
end of the 2nd cycle of vaccination and after IL-2 administration. These 
data imply that the raise in Tregs induced by IL-2 was not limiting the 
expansion of antigen-specific T cells evaluated as percentage of pentamer 
positive CD8+ T cells.  In order to assess whether Tregs were negatively 
shaping the functional activation of antigen-specific CD8+ T cells, the 
frequency of CD8+T responding to each peptide used as vaccine was 
evaluated by IFN-γ ELISpot assays at different time points during the 
vaccination course. Figure 5B reports the kinetic of peptide-specific 
CD8+ T cell induction for two vaccinated patients, namely Pt#1 and 
Pt#3. Of note, for both patients, frequency of peptide specific CD8+ T 
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cells became detectable after the 2nd vaccination and although IL-2 
administration led to strong increase in the Treg frequency (Figure 5B, 
bars in the histograms), the number of CD8+ T cells producing IFN-γ  in 
response to the antigenic peptide stimulation remained stable or was 
further increased. This trend was confirmed in all the analyzed patients 
(Filipazzi et al., manuscript submitted).   
Thus circulating Tregs boosted by IL-2 administered in a vaccination 
setting are not hampering the immune response of these patients to the 
vaccine.  Our results are in agreement with recent findings showing that 
in a multicentre trial of gp100 peptide vaccine plus IL-2, boost of  Tregs 
defined as CD4+CD25+Foxp3+ not only was not detrimental to immune 
response, but indeed patients who displayed a higher increase in their 
circulating Tregs had better clinical response (48). 
In light of the results of our phenotypic and functional analysis, we can 
conclude that IL-2 boosted CD4+CD25+Foxp3+ T cells include 
conventional activated T cells, suppressive Tregs and Tregs that in the 
pro-inflammatory environment created by the vaccine display functional 
plasticity. The balance among these different functional T cell subsets is 
likely influencing the immunological and clinical outcome of the treated 
patients.  
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LEGENDS 
 
Figure 1. Tregs are modulated after CTX and IL-2 administration. 
Patients’ PBMCs collected at different time points during vaccination (A) 
or observation period (D) (see Supplementary Figure 1S for details) were 
stained with anti-CD4, -CD25 and -Foxp3 mAbs (Treg markers) and 
analyzed by FACS. Graphs show the percentage distribution of 
CD4+CD25hiFoxp3+ Tregs in gated CD4+ T subset at different time 
points. Histograms (B) and (E) indicate the percentage reduction of 
CD4+CD25hiFoxp3+ Tregs after CTX administration (P1 compared to 
P0) in vaccine and control arm respectively. Histograms (C) and (F) repot 
the fold increase of CD4+CD25hiFoxp3+ Tregs after IL-2 administration 
(P6 compared to P4) in vaccinated and control patients respectively. P 
values calculated with Wilcoxon statistical test. 
 
Figure 2. TGF-β1 producing Tregs show a significant increase after 
IL-2 administration. Staining for Treg markers and intracellular staining 
for TGF-β1 were performed in patients’ PBMCs collected at different 
time points upon ex-vivo activation with anti-CD3/CD28 beads. The 
percentage of TGF-β1+ Tregs in CD4 lymphocytes is shown in graphs; 
vaccinated (A) and control (B) patients. P value calculated with 
Wilcoxon statistical test. 
 
Figure 3. Tregs expanded by IL-2 exert suppressive activity. 
Proliferation of CFSE-labeled CD4+CD25− peripheral blood T cells 
stimulated by anti-CD3/CD28 beads was assessed after 72h in the 
absence (unshaded histograms) or in the presence (shaded histograms) of  
autologous Tregs at 1:1 ratio  (A)  or at decreasing ratio of Tregs (B). 
CD4+CD25− responder T cells (P0 CD25neg) were isolated from PBMCs 
of patient # 4 at week -1 before the initiation of vaccination (see 
supplementary Figure 1S); Tregs were purified from PBMCs collected at 
week -1 (P0 Tregs) of the same patient or after IL-2 administration (P6 
Tregs). Proliferation is shown as FACS data analysis and inhibition of the 
proliferation is reported as mean percentage of two technical replicates.  
 
Figure 4. IL-2 increases both Treg and conventional CD4+ T cell 
frequency. CD4+ T cell subsets, defined by the FACS expression of 
CD45RA and CD25 according to Miyara et al. (18), in PBMCs pre- and 
post-IL-2 administration (P4 versus P6) of patient #33 are represented in 
Dot Plots. Fr. a= CD45RAnegCD25low (T conv) and Fr. b= 
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CD45RAnegCD25hi (Tregs), (A). Comparison between percentage 
distributions pre- and post-IL-2 (P4 versus P6) of these three 
subpopulations are shown for 6 vaccinated patients (B). Mean percentage 
expression of Ki67, T-bet and IFN-γ pre- and post-IL-2 (P4 versus P6) is 
reported as histogram in Fr. a (C) and Fr. b (D) (n=3 vaccinated patients; 
error bar represents SEM). Percentage distribution of IFN-γ+/activated 
Tregs  in CD4+ lymphocytes of PBMCs collected at different time points 
is shown for vaccinated (left panel) and control (right panel) patients; p 
value calculated with Wilcoxon statistical test (E).  
 
Figure 5. CD8+ T cell response to the vaccine peptides is not affected 
by Treg expansion. PBMCs of vaccinated patients were analyzed ex-
vivo by the indicated A2/peptide pentamer staining (a = gp100; b = 
melanA/MART1; c = NY-ESO-1; d = SVV-1) at the indicated time 
points; percentage of pentamer positive cells is calculated in CD8+ gate; 
p values were calculated with Wilcoxon test (A). For each time point, 
CD8+ T-cell response to the vaccine peptides, measured by IFN-γ-
ELISpot assay is reported together with the percentage of 
CD4+CD25hiFoxp3+Tregs in PBMCs of patients Pt #1 and Pt #3. 
 
Figure 1S. Schematic representation of the vaccination schedule. V= 
peptide vaccine made of HLA-A*0201-restricted (Melan-A/MART-
1[27L], gp100[210M], NY-ESO-1[165V], and Survivin[97M]) 250 µg 
each, emulsified in Montanide ISA-51. CTX= Cyclophosphamide i.v. 
300mg/m2. IL-2 s.c. 3x106 IU/day for 3 days. P= blood samples collected. 
 
Figure 2S. Frequency of Tregs in melanoma patients enrolled in the 
trial is enriched as compare to that of healthy donors. PBMCs of 
healthy donors (HD) and PBMCs of melanoma patients (PTs) collected 1 
week before being enrolled in the study were stained with anti-CD4, -
CD25 and -Foxp3 mAbs and analyzed by FACS. Graphs show the 
percentage distribution of CD25hiFoxp3+ (A) and CD25+Foxp3+ T cells 
(B) in gated CD4+ T cells. P values were calculated with Student’s t-
Test.  
 
Figure 3S. IL-2 induces the expansion of the CD4+ compartment. 
PBMCs of melanoma patients were analyzed by FACS for CD4 
expression in the lymphocyte region (G1) at different time points during 
vaccination (A) or observation (B). Significant p values were calculated 
with Wilcoxon test. 
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Figure 4S. Modulation of CD4+CD25+Foxp3+ T cells. Panel A and B 
show the frequency of CD25+Foxp3+ T cells in CD4 region in patients 
PBMCs collected at different time points; patients enrolled in the 
vaccination (A) or in the control arm (B). P value calculated with 
Wilcoxon statistical test. 
 
Figure 5S. IL-2 mediated Treg boost is transient. Graph shows the 
frequency profile of CD25hiFoxp3+ T cells in gated CD4 lymphocytes in 
PBMCs of Pt # 1 collected at different time points during vaccination  
(A); vaccination schedule and points of PBMCs collection is reported 
(B). 
 
Figure 6S. Modulation of TGF-β+ Tregs after CTX administration. 
Histograms show the frequency of CD25hiFoxp3+ T cells in gated CD4 
lymphocytes, while points and connection lines indicate the frequency of 
TGF-β+ Tregs in CD4 cells pre- and post-CTX treatment (P0-P1) in three 
vaccinated patients (Pt # 8, Pt # 9, Pt # 28); data of two control patients 
(Pt # 17, Pt # 18), at the same time course in the vaccination schedule, are 
reported. 
 
Figure 7S. Concentration of IL-12p70 in patients’ sera increases after 
vaccination. Histograms represent the IL-12p70 release, indicated as 
pg/ml, in the sera of healthy donors (HD, n=10), control patients (CRL, 
n=6) and vaccinated patients (Vax, n=8) before (pre) and after (post) 
vaccination. Error bar represents SEM. 
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